<PAGE> 1
As filed with the Securities and Exchange Commission
on August 31, 1995
REGISTRATION NO. 33-
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
-----------------
MEDITRUST
(Exact name of registrant as specified in governing instruments)
Massachusetts 04-6532031
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
197 First Avenue
Needham Heights, Massachusetts 02194
(617) 433-6000
(Address, including zip code, and telephone number,
including area code, of registrant's
principal executive offices)
-----------------
ABRAHAM D. GOSMAN
Chairman and Chief Executive Officer
MEDITRUST
197 First Avenue
Needham Heights, Massachusetts 02194
(617) 433-6000
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Copies of communications to:
MICHAEL J. BOHNEN, ESQUIRE
NUTTER, McCLENNEN & FISH
One International Place
Boston, MA 02110-2699
(617) 439-2000
Approximate date of commencement of proposed sale to public: From time to
time after the effective date of this Registration Statement.
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. / /
If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or
reinvestment plans, check the following box. /X/
<PAGE> 2
CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
=========================================================================================================
Title of Each Class Amount to Be Proposed Maximum Proposed Amount of
of Securities Being Registered Offering Price per Maximum Registration Fee
Registered Unit Aggregate Offering (2)
Price (1)
- ---------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Shares of Beneficial
Interest and Debt
Securities and
Warrants for Shares (5) (5) $300,000,000 $103,448.28
of Beneficial
Interest and Debt
Securities Issuable
in Series(3)(4)
=========================================================================================================
<FN>
(1) In no event will the aggregate maximum offering price of all securities
issued pursuant to this Registration Statement exceed $300,000,000, or if
any Debt Securities are issued with an original issue discount, such
greater amount as shall result in an aggregate offering price of
$300,000,000. Any securities registered hereunder may be sold separately
or as units with other securities registered hereunder.
(2) Determined pursuant to Rule 457(o) under the Securities Act of 1933, as
amended.
(3) There is also being registered an indeterminate number of Shares of
Beneficial Interest as may be issued upon conversion of the Debt
Securities or exercise of the Securities Warrants registered hereby.
(4) There is also being registered hereunder an indeterminate number of Debt
Securities Warrants and Share Warrants representing rights to purchase
Debt Securities and Shares of Beneficial Interest, respectively,
registered pursuant to this Registration Statement.
(5) Not applicable pursuant to General Instructions II.D of Form S-3 under
the Securities Act of 1933, as amended.
The Registrant hereby amends this Registration Statement on such date or
dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that
this Registration Statement shall thereafter become effective in
accordance with Section 8(a) of the Securities Act of 1933, or until the
Registration Statement shall become effective on such date as the
Commission, acting pursuant to said Section 8(a), may determine.
</TABLE>
<PAGE> 3
PROSPECTUS
MEDITRUST
Shares of Beneficial Interest,
Debt Securities and/or Securities Warrants
------------------
Meditrust, a Massachusetts business trust (together with its subsidiaries
unless the context otherwise requires, the "Company"), is a real estate
investment trust under the Internal Revenue Code of 1986, as amended, which may
offer from time to time, in one or more series, its debt securities (the "Debt
Securities"), warrants to purchase Debt Securities (the "Debt Securities
Warrants"), shares of beneficial interest, without par value (the "Shares"), and
warrants to purchase Shares (the "Share Warrants"). The Debt Securities Warrants
and the Share Warrants are collectively referred to herein as the "Securities
Warrants." The Debt Securities, Shares and Securities Warrants are collectively
referred to herein as the "Securities." The Securities will have an aggregate
offering price of $300,000,000 and will be offered in amounts, at prices and
on terms to be determined at the time of offering.
In the case of Debt Securities, the specific title, the aggregate principal
amount, the purchase price, the maturity, the rate and time of payment of any
interest, any redemption or sinking fund provisions, any conversion provisions
and any other specific term of the Debt Securities will be set forth in an
accompanying supplement to this Prospectus (the "Prospectus Supplement"). In the
case of Shares, the specific number of Shares and issuance price per Share will
be set forth in an accompanying Prospectus Supplement. In the case of Securities
Warrants, the duration, offering price, exercise price and detachability, if
applicable, will be set forth in an accompanying Prospectus Supplement. The
Prospectus Supplement will also disclose whether the Securities will be listed
on a national securities exchange and if they are not to be listed, the possible
effects thereof on their marketability.
The Securities may be sold: (i) directly by the Company; (ii) through
underwriting syndicates represented by one or more managing underwriters, or by
one or more underwriters without a syndicate; and (iii) through agents
designated from time to time. The names of any underwriters or agents of the
Company involved in the sale of the Securities in respect of which this
Prospectus is being delivered and any applicable commissions or discounts will
be set forth in an accompanying Prospectus Supplement. See "Plan of
Distribution." The net proceeds to the Company from such sale also will be set
forth in the Prospectus Supplement.
The Company's shares are traded on the New York Stock Exchange under the
symbol "MT." On August 30, 1995, the closing sale price of the Shares on the New
York Stock Exchange was $33.00.
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS
THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES
COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS
PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS
A CRIMINAL OFFENSE.
----------------
THE ATTORNEY GENERAL OF THE STATE OF NEW YORK HAS NOT PASSED ON OR
ENDORSED THE MERITS OF THIS OFFERING. ANY REPRESENTATION TO
THE CONTRARY IS UNLAWFUL.
----------------
This Prospectus may not be used to consummate sales of Securities unless
accompanied by a Prospectus Supplement.
----------------
The date of this Prospectus is August 31, 1995.
<PAGE> 4
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith files reports, proxy statements and other information with the
Securities and Exchange Commission (the "Commission"). Such reports, proxy
statements and other information can be inspected and copied at the public
reference facilities maintained by the Commission at Room 1024 of the offices of
the Commission, Judiciary Plaza, 450 Fifth Street, N.W., Washington, D.C. 20549,
or at the regional offices of the Commission located at Seven World Trade
Center, 13th Floor, New York, New York 10048 and Suite 1400, Northwestern Atrium
Center, 500 West Madison Street, Chicago, Illinois 60661. Copies of such
material can be obtained from the principal offices of the Commission at
Judiciary Plaza, 450 Fifth Street, N.W., Washington D.C. 20549, at prescribed
rates. Reports, proxy materials and other information concerning the Company can
also be inspected at the offices of the New York Stock Exchange, 20 Broad
Street, Room 1102, New York, New York 10005.
The Company has filed with the Commission a Registration Statement on Form
S-3 (together with all amendments and exhibits thereto, the "Registration
Statement") under the Securities Act of 1933, as amended (the "Securities Act").
This Prospectus and any accompanying Prospectus Supplement do not contain all
the information set forth in the Registration Statement, certain parts of which
are omitted in accordance with the rules and regulations of the Commission. For
further information, reference is made to the Registration Statement, copies of
which may be obtained upon payment of a fee prescribed by the Commission, or may
be examined free of charge at the principal office of the Commission in
Washington, D.C.
Statements made in this Prospectus and any accompanying Prospectus
Supplement as to the contents of any contract or other document referred to are
not necessarily complete, and reference is made to the copy of such contract or
other document filed as an exhibit to the Registration Statement, each such
statement being qualified in all respects by such reference.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The Company hereby incorporates by reference into this Prospectus its
Annual Report on Form 10-K for the fiscal year ended December 31, 1994 and its
Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 1995, which
shall be deemed to be a part hereof. The discussion of Federal income tax
treatment of the Company and its shareholders which is contained in the
Company's Current Report on Form 8-K dated March 4, 1992, including any
amendment or report filed for the purpose of updating such discussion, is hereby
incorporated by reference into this Prospectus and shall be deemed to be a part
hereof.
-2-
<PAGE> 5
All documents filed by the Company with the Commission pursuant to
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date
hereof and prior to the termination of the offering of the Securities offered
hereby shall be deemed to be incorporated by reference into this Prospectus and
to be a part hereof from the date of filing such documents. Any statement
contained herein or in a document incorporated or deemed to be incorporated by
reference herein shall be deemed to be modified or superseded for purposes of
this Prospectus to the extent that a statement contained herein or in a
subsequently filed document, as the case may be, which also is or is deemed to
be incorporated by reference herein, modifies or supersedes such statement. Any
such statement so modified or superseded shall not be deemed, except as so
modified or superseded, to constitute a part of this Prospectus.
The Company will provide without charge to each person to whom this
Prospectus is delivered, upon the written or oral request of such person, a copy
(without exhibits) of any or all documents incorporated by reference into this
Prospectus. Requests for such copies should be directed to Lisa P. McAlister,
Vice President and Treasurer, Meditrust, 197 First Avenue, Needham Heights,
Massachusetts 02194, telephone (617) 433-6000.
----------------
THE DECLARATION OF TRUST ESTABLISHING THE COMPANY, DATED AUGUST 6, 1985,
AS AMENDED (THE "DECLARATION"), A COPY OF WHICH IS DULY FILED IN THE OFFICE OF
THE SECRETARY OF STATE OF THE COMMONWEALTH OF MASSACHUSETTS, PROVIDES THAT THE
NAME "MEDITRUST" REFERS TO THE TRUSTEES UNDER THE DECLARATION COLLECTIVELY AS
TRUSTEES, BUT NOT INDIVIDUALLY OR PERSONALLY; AND THAT NO TRUSTEE, OFFICER,
SHAREHOLDER, EMPLOYEE OR AGENT OF THE COMPANY SHALL BE HELD TO ANY PERSONAL
LIABILITY, JOINTLY OR SEVERALLY, FOR ANY OBLIGATION OF, OR CLAIM AGAINST, THE
COMPANY. ALL PERSONS DEALING WITH THE COMPANY, IN ANY WAY, SHALL LOOK ONLY TO
THE ASSETS OF THE COMPANY FOR THE PAYMENT OF ANY SUM OR THE PERFORMANCE OF ANY
OBLIGATION.
-3-
<PAGE> 6
THE COMPANY
Meditrust is the largest dedicated health care real estate investment
trust in the United States, based on its gross real estate investments of $1.7
billion as of June 30, 1995. The objective of the Company is to enable
shareholders to participate in the investment in health care related facilities
held primarily for the production of cash flows to be distributed to
shareholders. In meeting this objective, the Company invests in high quality
facilities that are managed by experienced operators and attempts to achieve
diversity in its property portfolio by sector of the health care industry,
geographic location, operator and form of investment.
As of June 30, 1995, the Company had investments in 285 facilities,
consisting of 240 long-term care facilities, 23 rehabilitation hospitals, six
psychiatric hospitals, five retirement living facilities, two alcohol and
substance abuse facilities, eight medical office buildings and one acute care
hospital. The properties are located in 34 different states and are operated by
33 health care companies. Of the 33 different operators, seven are, or are owned
by, publicly-traded companies (i.e., Sun Healthcare Group, Inc., Continental
Medical Systems, Inc. (a subsidiary of Horizon Healthcare Corp.), Geriatric and
Medical Centers, Inc., OrNda Healthcorp., Integrated Health Services, Inc.,
HealthSouth Corporation and Mariner Health Group, Inc.), and constitute 44% of
the Company's gross real estate investments.
During the first six months of 1995, the Company committed $243 million to
new real estate investments, of which $172 million was funded. Of these amounts,
$126 million was committed and $55 million was funded during the quarter ended
June 30, 1995.
The Company's real estate investments are either owned by the Company or
secured by a mortgage lien. As of June 30, 1995 permanent mortgage loans
constituted 56%, sale/leaseback transactions constituted 40%, and development
mortgage financing constituted 4% of the Company's portfolio as measured by
gross real estate investments. The leases and mortgages provide for rental or
interest rates which generally range from 9.5% to 13.5% per annum of the
acquisition price or mortgage amount. The leases and mortgages generally provide
for an initial term of 10 years, with the leases having one or more five-year
renewal options. The leases and mortgages also provide for additional rent and
interest which are generally based upon a percentage of increased revenues over
specific base period revenues of the related properties. For the year ended
December 31, 1994, the aggregate amount of additional rent and interest was
approximately $8.2 million compared to $8.7 million for the year ended December
31, 1993.
In addition, the Company usually obtains guarantees from the parent
corporation, if any, of the operator or affiliates or individual principals of
the operator. Most obligations are backed by letters of credit or pledges of
certificates of deposit which cover from three
-4-
<PAGE> 7
to twelve months of lease or mortgage payments. In addition, permanent mortgage
and development mortgage loans generally are cross-collateralized with any other
mortgage and development loans, leases or other agreements between the Company
and the same operator or any affiliated operators. Leases and mortgage loans
generally are cross-defaulted with any other leases or mortgages between the
Company and the same operator or any affiliated operators. With respect to
development mortgage loans, the Company generally requires guaranteed maximum
price construction contracts, performance completion bonds or guarantees and
cost overrun guarantees. The Company enters into a development mortgage loan
when the Company will also be the permanent owner or mortgage lender. In making
its investment decisions, the Company reviews, among other criteria, the
operational viability of the facility, the experience and competency of the
operator and the financial strength of the guarantor.
In making its investment decisions, the Company reviews, among other
criteria, the operational viability of the facility, the experience and
competency of the operator and the financial strength of the guarantor. From
time to time, the Company enters into transactions with related parties. As of
June 30, 1995, the Company had total commitments of $101 million, of which $37
million was funded, to companies in which Abraham D. Gosman, the Company's Chief
Executive Officer, has an ownership interest. The Company expects to enter into
additional transactions with related parties in the future. All of the terms and
conditions of such transactions are subject to approval by the independent
Trustees of the Company. The Board of Trustees believes that the terms of the
transactions which the Company has entered into with related parties are not
less favorable to the Company than those prevailing at the time for comparable
transactions with unrelated persons.
The Company was organized to qualify, and intends to continue to operate,
as a real estate investment trust in accordance with Federal tax laws and
regulations. So long as the Company so complies, with limited exceptions, the
Company will not be taxed under Federal income tax laws on that portion of its
taxable income that it distributes to its shareholders. The Company has
distributed, and intends to continue to distribute, substantially all of its
real estate investment trust taxable income to shareholders.
In order to meet its ongoing capital requirements for additional
investments, the Company may raise additional equity capital through the sale of
Shares, Debt Securities, Share Warrants or Debt Securities Warrants or draw
against its revolving bank lines of credit.
The Company is a self-administered real estate investment trust, with its
principal executive offices at 197 First Avenue, Needham Heights, Massachusetts
02194. Its telephone number is (617) 433-6000.
-5-
<PAGE> 8
HEALTH CARE REFORM AND REGULATION
Many of the operators with which the Company does business rely on
government reimbursement, primarily Medicare and Medicaid, for a significant
portion of their operating revenues. During a recent session of the United
States Congress, there was active consideration of various proposals for
national health care reform, including the administration's proposal to cap
national health care spending and the future growth of Medicare and Medicaid
funding. No such legislation was passed during the 1994 session of Congress.
Such legislation may be reintroduced during current or future sessions of
Congress, although it is not possible to predict whether and when health care
reform legislation will be passed by Congress and, if passed, what features such
legislation will contain or the effect it may have on the nursing home, assisted
living or rehabilitation care industries, the reimbursements levels available to
health care providers or on the health care industry in general.
From time to time, Medicaid, Medicare and other governmental payers have
reviewed the billing practices of many health care facilities operators
including certain of the operators with which the Company does business. It is
unclear what impact such reviews may have on these operators. The Company does
not believe, however, that any adverse findings against these operators would
materially affect the Company's financial position.
<TABLE>
RATIO OF EARNINGS TO FIXED CHARGES
<CAPTION>
Six-month
Year Ended December 31, Period Ended
------------------------
1990 1991 1992 1993 1994 June 30,1995
----------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Ratio 1.67 l.60 1.88 2.02 2.19 2.63
</TABLE>
For the purpose of calculating the ratio of earnings to fixed charges for
the years ended December 31, 1990, 1991, 1992, 1993 and 1994 and for the
six-month period ended June 30, 1995, net income has been added to interest
expense and that sum has been divided by such interest expense.
USE OF PROCEEDS
Unless otherwise specified in the Prospectus Supplement which accompanies
this Prospectus, the net proceeds from the sale of the Securities offered from
time to time hereby will be used for general business purposes, including the
repayment of bank lines of credit, if any, outstanding, and investments in
health care facilities. As of August 14, 1995, $75,000,000 was outstanding under
the Company's bank lines of credit. All currently
-6-
<PAGE> 9
outstanding loans under the Company's bank lines of credit mature prior to July
1, 1997 and accrue interest at the lenders' respective prime rates or the London
Interbank Offering Rate plus 1.00%. Pending such uses, the net proceeds will be
invested in short-term, interest-bearing, direct obligations issued or
guaranteed by the United States, certificates of deposit or accounts, or
investment grade commercial paper, consistent with the Company's qualification
as a real estate investment trust, the Company's Restated Declaration of Trust,
as amended (the "Declaration"), and the Company's agreements with its lenders.
DESCRIPTION OF SHARES
There is no limit on the number of Shares the Company is authorized to
issue. Shares may be issued by the Board of Trustees without any vote of the
shareholders. The outstanding Shares are of one class and without par value. The
following description is qualified in all respects by reference to the
Declaration and the By-laws of the Company, copies of which are incorporated by
reference as exhibits to the Registration Statement of which this Prospectus is
a part.
Shares of Beneficial Interest. All Shares participate equally in dividends
and in net assets available for distribution to shareholders on liquidation or
termination of the Company, have one vote per Share on all matters submitted to
a vote of the shareholders and do not have cumulative voting rights in the
election of Trustees. The Shares offered hereby will be validly issued, fully
paid and nonassessable by the Company upon issuance.
Redemption. For the Company to qualify as a real estate investment trust
under the Internal Revenue Code of 1986, as amended (the "Code"), in any taxable
year, not more than 50% of its outstanding Shares may be owned by five or fewer
individuals and Shares must be owned by 100 or more persons during at least 335
days of a taxable year of 12 months or during a proportionate part of a shorter
taxable year. In order to meet these requirements, the Trustees have the power
to redeem or prohibit the transfer of a sufficient number of Shares selected in
a manner deemed appropriate to maintain or bring the ownership of the Shares
into conformity with such requirements. In connection with the foregoing, if the
Trustees shall, at any time and in good faith, be of the opinion that direct or
indirect ownership of at least 9.9% or more of the Shares has or may become
concentrated in the hands of one beneficial owner, the Trustees shall have the
power (i) by lot or other means deemed equitable by them to call for the
purchase from any shareholder of the Company of a number of Shares sufficient,
in the opinion of the Trustees, to maintain or bring the direct or indirect
ownership of Shares of such owner to a level of no more than 9.9% of the
outstanding Shares, and (ii) to refuse to transfer or issue Shares to any person
whose acquisition of such Shares would cause a beneficial holder to hold in
excess of 9.9% of the outstanding Shares. Further, any transfer of Shares that
would create a beneficial owner of more than 9.9% of the outstanding Shares
shall be deemed void and the intended transferee shall be deemed never to have
had an interest therein. The purchase price for any Shares so redeemed shall be
equal to the fair market value of the Shares reflected
-7-
<PAGE> 10
in the closing sales price for the Shares, if then listed on a national
securities exchange, or the average of the closing sales price for the Shares if
then listed on more than one national securities exchange, or if the Shares are
not then listed on a national securities exchange, the latest bid quotation for
the Shares if then traded over-the-counter, on the last business day immediately
preceding the day on which notices of such acquisition are sent by the Company.
From and after the date fixed for purchase by the Trustees, the holder of any
Shares so called for purchase shall cease to be entitled to distributions,
voting rights and other benefits with respect to such Shares, except the right
to payment of the purchase price for the Shares.
The foregoing provisions may have the effect of discouraging unilateral
tender offers or other takeover proposals which certain shareholders might deem
in their interest or in which they might receive a substantial premium. The
provisions could also have the effect of insulating current management against
the possibility of removal and could, by possibly reducing temporary
fluctuations in market price caused by accumulations of Shares, deprive
shareholders of opportunities to sell at a temporarily higher market price.
Additional Provisions. The Declaration provides that annual meetings of
shareholders are to be held within six months after the end of each fiscal year
and special meetings of the shareholders may be called by the President of the
Company, a majority of the Trustees or a majority of the Independent Trustees
(defined in the Declaration) and shall be called upon the written request of the
holders of 10% or more of the outstanding Shares.
Whenever any action is to be taken by the shareholders, it shall, except
as otherwise clearly indicated in the Declaration of Trust, be authorized by
holders of a majority of the Shares then outstanding and entitled to vote
thereon. Notwithstanding the foregoing, at all elections of Trustees, voting by
shareholders shall be conducted under the non-cumulative method and the election
of Trustees shall be by the affirmative vote of the holders of Shares
representing a plurality of the Shares then outstanding which are present in
person or by proxy at a meeting in which a quorum is present.
Whenever shareholders are required or permitted to take any action (unless
a vote at a meeting is specifically required, as with respect to termination or
amendment of the Declaration), such action may be taken without a meeting by
written consents setting forth the action so taken, signed by the holders of a
majority (or such higher percentage as may be specified) of the outstanding
Shares that would be entitled to vote thereon at a meeting.
Except with respect to matters on which a shareholders' vote is
specifically required by the Declaration, no action taken by the shareholders at
any meeting shall in any way bind the Trustees.
The Shares have no preemptive, conversion, exchange, sinking fund or
appraisal rights.
-8-
<PAGE> 11
The Declaration provides that shareholders of the Company shall not be
subject to any liability for the acts or obligations of the Company and that, as
far as is practicable, each written agreement of the Company is to contain a
provision to that effect. No personal liability will attach to the shareholders
for claims under any contract containing such a provision in writing where
adequate notice is given of such provision, except possibly in a few
jurisdictions. With respect to all types of claims in such jurisdictions and
with respect to tort claims, contract claims where the shareholder liability is
not disavowed as described above, claims for taxes and certain statutory
liabilities in other jurisdictions, a shareholder may be held personally liable
to the extent claims are not satisfied by the Company. However, the Declaration
provides that, upon payment of any such liability, the shareholder will be
entitled to reimbursement from the general assets of the Company. The Trustees
intend to conduct the operations of the Company, with the advice of counsel, in
such a way as to avoid, as far as is practicable, the ultimate liability of the
shareholders of the Company. For example, almost all of the real estate and all
of the mortgages included in the assets of the Company are held by corporate
subsidiaries. The Trustees do not intend to provide insurance covering such
risks to shareholders.
Transfer Agent and Registrar. Fleet National Bank, Providence, Rhode
Island, acts as transfer agent and registrar of the Shares.
DESCRIPTION OF DEBT SECURITIES
The Prospectus Supplement will describe certain terms of any Debt
Securities offered hereby, including (i) the title of such Debt Securities; (ii)
any limit on the aggregate principal amount of such Debt Securities and their
purchase price; (iii) the date or dates on which such Debt Securities will
mature; (iv) the rate or rates per annum (or manner in which interest is to be
determined) at which such Debt Securities will bear interest, if any, and the
date from which such interest, if any, will accrue; (v) the dates on which such
interest, if any, on such Debt Securities will be payable and the regular record
dates for such interest payment dates; (vi) any mandatory or optional sinking
fund or analogous provisions; (vii) additional provisions, if any, for the
defeasance of such Debt Securities; (viii) the date, if any, after which and the
price or prices at which such Debt Securities may, pursuant to any optional or
mandatory redemption or repayment provisions, be redeemed and the other detailed
terms and provisions of any such optional or mandatory redemption or repayment
provisions; (ix) whether such Debt Securities are to be issued in whole or in
part in registered form represented by one or more registered global securities
(a "Registered Global Security") and, if so, the identity of the depository for
such Registered Global Security or Securities; (x) certain applicable United
States Federal income tax consequences; (xi) any provisions relating to security
for payments due under such Debt Securities; (xii) any provisions relating to
the conversion or exchange of such Debt Securities into or for Shares or Debt
Securities of another series; (xiii) any provisions relating to the ranking of
such Debt Securities in right of payment as compared to other obligations of the
Company; (xiv) the denominations in which such Debt Securities are authorized to
be
-9-
<PAGE> 12
issued; (xv) the place or places where principal of, premium, if any, and
interest, if any, on such Debt Securities will be payable; (xvi) whether such
debt Securities are to be issued pursuant to an indenture of trust; and (xvii)
any other specific term of such Debt Securities, including any additional events
of default or covenants provided for with respect to such Debt Securities, and
any terms that may be required by or advisable under applicable laws or
regulations.
The Debt Securities may be issued in one or more series under an Indenture
to be executed by the Company and a trustee (the "Trustee"), a form of which is
included as an exhibit to the Registration Statement of which this Prospectus is
a part (the "Indenture"). The terms of the Debt Securities may include those
stated in the Indenture and those made a part of the Indenture (before any
supplements) by reference to the Trust Indenture Act of 1939, as amended.
The following is a summary of certain provisions of the Indenture and does
not purport to be complete and is qualified in its entirety by reference to the
detailed provisions of the Indenture, including the definitions of certain terms
therein to which reference is hereby made, for a complete statement of such
provisions. Wherever particular provisions or sections of the Indenture or terms
defined therein are referred to herein, such provisions or definitions are
incorporated herein by reference.
General. The Indenture does not limit the aggregate principal amount of
Debt Securities that may be issued thereunder and provides that Debt Securities
may be issued from time to time in one or more series.
Conversion Rights. The terms, if any, on which Debt Securities of any
series may be converted into Shares or Debt Securities of another series will be
set forth in the Prospectus Supplement relating thereto. To protect the
Company's status as a real estate investment trust ("REIT"), the holders of Debt
Securities of any series ("Holders") may not convert any Debt Security, and such
Debt Security shall not be convertible by any Holder, if as a result of such
conversion any person would then be deemed to beneficially own, directly or
indirectly, 9.9% or more of the then outstanding Shares.
The conversion price will be subject to adjustment under certain
conditions, including (i) the payment of dividends (and other distributions) in
Shares on any class of shares of the Company; (ii) subdivisions, combinations
and reclassifications of Shares; (iii) the issuance to all or substantially all
holders of Shares of rights or warrants entitling them to subscribe for or
purchase Shares at a price per Share (or having a conversion price per Share)
less than the then current market price; and (iv) distributions to all or
substantially all holders of Shares or shares of any other class, or evidences
of indebtedness or assets (including securities, but excluding those rights,
warrants, dividends and distributions referred to above and dividends and
distributions not prohibited under the terms of the Indenture) of the Company,
subject to the limitation that all adjustments by reason of any of the foregoing
would not be made until they
-10-
<PAGE> 13
result in a cumulative change in the conversion price of at least 1%. In the
event the Company shall effect any capital reorganization or reclassification of
its Shares or shall consolidate or merge with or into any trust or corporation
(other than a consolidation or merger in which the Company is the surviving
entity) or shall sell or transfer substantially all its assets to any other
trust or corporation, the Holders shall, if entitled to convert such Debt
Securities at any time after such transaction, receive upon conversion thereof,
in lieu of each Share into which the Debt Securities of such series would have
been convertible prior to such transaction, the same kind and amount of stock
and other securities, cash or property as shall have been issuable or
distributable in connection with such transaction with respect to each Share.
A conversion price adjustment made according to the provisions of the Debt
Securities of any series (or the absence of provision for such an adjustment)
might result in a constructive distribution to the Holders of Debt Securities of
such series or holders of Shares that would be subject to taxation as a
dividend. The Company may, at its option, make such reductions in the conversion
price, in addition to those set forth above, as the Board of Trustees of the
Company deems advisable to avoid or diminish any income tax to holders of Shares
resulting from any dividend or distribution of Shares (or rights to acquire
Shares) or from any event treated as such for income tax purposes or for any
other reason. The Board of Trustees will also have the power to resolve any
ambiguity or correct any error in the provisions relating to the adjustment of
the conversion price of the Debt Securities of such series and its actions in so
doing shall be final and conclusive.
Fractional Shares will not be issued upon conversion, but, in lieu
thereof, the Company will pay a cash adjustment based upon market price.
The Holders of Debt Securities of any series at the close of business on
an interest payment record date shall be entitled to receive the interest
payable on such Debt Securities on the corresponding interest payment date
notwithstanding the conversion thereof. However, Debt Securities surrendered for
conversion during the period from the close of business on any record date for
the payment of interest to the opening of business on the corresponding interest
payment date must be accompanied by payment of an amount equal to the interest
payable on such interest payment date. Holders of Debt Securities of any series
who convert Debt Securities of such series on an interest payment date will
receive the interest payable by the Company on such date and need not include
payment in the amount of such interest upon surrender of such Debt Securities
for conversion. Except as aforesaid, no payment or adjustment is to be made on
conversion for interest accrued on the Debt Securities of any series or for
dividends on Shares.
Optional Redemption. The Debt Securities of any series that are
convertible into Shares will be subject to redemption, in whole or from time to
time in part, at any time for certain reasons intended to protect the Company's
status as a REIT at the option of the Company on at least 30 days' prior notice
by mail at a redemption price equal to 100% of the principal
-11-
<PAGE> 14
amount, plus interest accrued to the date of redemption. Except as otherwise set
forth in the accompanying Prospectus Supplement, the Company may exercise its
redemption powers solely with respect to the securities of the security holder
or holders which pose a threat to the Company's REIT status and only to the
extent deemed necessary by the Company's Board of Trustees to preserve such
status. (See "Redemption" under "Description of Shares".)
Dividends, Distributions and Acquisitions of Shares of Beneficial
Interest. The Indenture provides that the Company will not (i) declare or pay
any dividend or make any distribution on its Shares or to holders of its Shares
(other than dividends or distributions payable in its Shares or other than as
the Company determines is necessary to maintain its status as a REIT) or (ii)
purchase, redeem or otherwise acquire or retire for value any of its Shares or
permit any subsidiary to do so, if at the time of such action an Event of
Default (as defined in the Indenture) has occurred and is continuing or would
exist immediately after giving effect to such action.
Additional Covenants. Any additional covenants of the Company with respect
to a series of the Debt Securities will be set forth in the Prospectus
Supplement relative thereto.
Modification of the Indenture. Under the Indenture, with certain
exceptions, the rights and obligations of the Company with respect to any series
of Debt Securities and the rights of Holders of such series may only be modified
by the Company and the Trustee with the consent of the Holders of at least a
majority in principal amount of the outstanding Debt Securities of such series.
However, without the consent of each Holder of any Debt Securities affected, an
amendment, waiver or supplement may not (i) reduce the principal of, or rate of
interest on, any Debt Securities; (ii) change the stated maturity date of the
principal of, or any installment of interest on, any Debt Securities; (iii)
waive a default in the payment of the principal amount of, or the interest on,
or any premium payable on redemption of, any Debt Securities; (iv) change the
currency for payment of the principal of, or premium or interest on, any Debt
Securities; (v) impair the right to institute suit for the enforcement of any
such payment when due; (vi) adversely affect any right to convert any Debt
Securities; (vii) reduce the amount of outstanding Debt Securities necessary to
consent to an amendment, supplement or waiver provided for in the Indenture; or
(viii) modify any provisions of the Indenture relating to the modification and
amendment of the Indenture or waivers of past defaults, except as otherwise
specified.
Events of Default, Notice and Waiver. Except as otherwise set forth in the
accompanying Prospectus Supplement, the following is a summary of certain
provisions of the Indenture relating to events of default, notice and waiver.
The following are Events of Default under the Indenture with respect to
any series of Debt Securities: (i) default in the payment of interest on the
Debt Securities of such series when due and payable, which continues for 30
days; (ii) default in the payment of principal of (and
-12-
<PAGE> 15
premium, if any) on the Debt Securities when due, at maturity, upon redemption
or otherwise, which continues for five Business Days; (iii) failure to perform
any other covenant of the Company contained in the Indenture or the Debt
Securities of such series which continues for 60 days after written notice as
provided in the Indenture; (iv) default under any bond, debenture or other
Indebtedness (as defined in the Indenture) of the Company or any subsidiary if
(a) either (x) such event of default results from the failure to pay any such
Indebtedness at maturity or (y) as a result of such event of default, the
maturity of such Indebtedness has been accelerated prior to its expressed
maturity and such acceleration shall not be rescinded or annulled or the
accelerated amount paid within ten days after notice to the Company of such
acceleration, or such Indebtedness having been discharged, and (b) the principal
amount of such Indebtedness, together with the principal amount of any other
such Indebtedness in default for failure to pay principal or interest thereon,
or the maturity of which has been so accelerated, aggregates $10,000,000 or
more; (v) certain events of bankruptcy, insolvency or reorganization relating to
the Company; and (vi) any other Event of Default provided with respect to the
Debt Securities of that series.
If an Event of Default occurs and is continuing with respect to the Debt
Securities of any series, either the Trustee or the Holders of a majority in
aggregate principal amount of the outstanding Debt Securities of such series may
declare the Debt Securities due and payable immediately.
The Indenture provides that the Trustee will, within 90 days after the
occurrence of any Default or Event of Default with respect to the Debt
Securities of any series, give to the Holders of Debt Securities notice of all
uncured Defaults and Events of Default known to it, but the Trustee will be
protected in withholding such notice if it in good faith determines that the
withholding of such notice is in the interest of such Holders, except in the
case of a default in the payment of the principal of (or premium, if any) or
interest on any of the Debt Securities of such series.
The Indenture provides that the Holders of a majority in aggregate
principal amount of the Debt Securities of any series then outstanding may
direct the time, method and place of conducting any proceedings for any remedy
available to the Trustee or exercising any trust or power conferred on the
Trustee with respect to the Debt Securities of such series. The right of a
Holder to institute a proceeding with respect to the Indenture is subject to
certain conditions precedent including notice and indemnity to the Trustee, but
the Holder has an absolute right to receipt of principal of (and premium, if
any) and interest on such Holder's Debt Securities on or after the respective
due dates expressed in the Debt Securities, and to institute suit for the
enforcement of any such payments.
The Holders of a majority in principal amount of the outstanding Debt
Securities of any series then outstanding may on behalf of the Holders of all
Debt Securities of such series waive certain past defaults, except a default in
payment of the principal of (or premium, if any) or
-13-
<PAGE> 16
interest on any Debt Securities of such series or in respect of certain
provisions of the Indenture which cannot be modified or amended without the
consent of the Holder of each outstanding Debt Securities of such series
affected thereby.
The Company will be required to furnish to the Trustee annually a
statement of certain officers of the Company stating whether or not they know of
any Default or Events of Default (as defined in the Indenture) and, if they have
knowledge of a Default or Event of Default, a description of the efforts to
remedy the same.
Consolidation, Merger, Sale or Conveyance. The Indenture provides that the
Company may merge or consolidate with, or sell or convey all or substantially
all of its assets to, any other trust or corporation, provided that (i) either
the Company shall be the continuing entity, or the successor entity (if other
than the Company) shall be an entity organized and existing under the laws of
the United States or a state thereof or the District of Columbia (although it
may, in turn, be owned by a foreign entity) and such entity shall expressly
assume by supplemental indenture all of the obligations of the Company under the
Debt Securities of any series and the Indenture, (ii) immediately after giving
effect to such transactions no Default or Event of Default shall have occurred
and be continuing, and (iii) the Company shall have delivered to the Trustee an
Officers' Certificate and opinion of counsel, stating that the transaction and
supplemental indenture comply with the Indenture. The Indenture does not contain
any provision requiring the Company to repurchase the Debt Securities of any
series at the option of the Holders thereof in the event of a leveraged buyout,
recapitalization or similar restructuring of the Company, even though the
Company's creditworthiness and the market value of the Debt Securities may
decline significantly as a result of such transaction. The Indenture does not
protect Holders of the Debt Securities of any series against any decline in
credit quality, whether resulting from any such transaction or from any other
cause.
Global Securities. The Debt Securities of a series may be issued in whole
or in part in global form (the "Global Securities"). The Global Securities will
be deposited with a depository (the "Depository"), or with a nominee for a
Depository, identified in the Prospectus Supplement. In such case, one or more
Global Securities will be issued in a denomination or aggregate denominations
equal to the portion of the aggregate principal amount of outstanding Debt
Securities of the series to be represented by such Global Security or
Securities. Unless and until it is exchanged in whole or in part for Debt
Securities in definitive form, a Global Security may not be transferred except
as a whole by the Depository for such Global Security to a nominee of such
Depository or by a nominee of such Depository to such Depository or another
nominee of such Depository or by such Depository or any such nominee to a
successor for such Depository or a nominee of such successor.
-14-
<PAGE> 17
The specific material terms of the depository arrangement with respect to
any portion of a series of Debt Securities to be represented by a Global
Security will be described in the Prospectus Supplement. The Company anticipates
that the following provisions will apply to all depository arrangements.
Upon the issuance of a Global Security, the Depository for such Global
Security will credit, on its book entry registration and transfer system, the
respective principal amounts of the Debt Securities represented by such Global
Security to the accounts of persons that have accounts with such Depository
("participants"). The accounts to be credited shall be designated by any
underwriters or agents participating in the distribution of such Debt
Securities. Ownership of beneficial interests in a Global Security will be
limited to participants or persons that may hold interests through participants.
Ownership of beneficial interests in such Global Security will be shown on, and
the transfer of that ownership will be effected only through records maintained
by the Depository for such Global Security (with respect to interests of
participants) or by participants or persons that hold through participants (with
respect to interests of persons other than participants). So long as the
Depository for a Global Security, or its nominee, is the registered owner of
such Global Security, such Depository or such nominee as the case may be, will
be considered the sole owner or Holder of the Debt Securities represented by
such Global Security for all purposes under the Indenture; provided, however,
that for purposes of obtaining any consents or directions required to be given
by the Holders of the Debt Securities, the Company, the Trustee and its agents
will treat a person as the holder of such principal amount of Debt Securities as
specified in a written statement of the Depository.
Principal, premium, if any, and interest payments, if any, on Debt
Securities represented by a Global Security registered in the name of a
Depository or its nominee will be made to such Depository or its nominee, as the
case may be, as the registered owner of such Global Security. None of the
Company, the Trustee or any Paying Agent for such Debt Securities will have any
responsibility or liability for any aspect of the records relating to or
payments made on account of beneficial ownership interests in such Global
Security or for maintaining, supervising or reviewing any records relating to
such beneficial ownership interests.
The Company expects that the Depository for any Debt Securities
represented by a Global Security, upon receipt of any payment of principal,
premium, if any, or interest will immediately credit participants' accounts with
payments in amounts proportionate to their respective beneficial interests in
the principal amount of such Global Security as shown on the records of such
Depository. The Company also expects that payments by participants will be
governed by standing instructions and customary practices, as is now the case
with the securities held for the accounts of customers registered in "street
names," and will be the responsibility of such participants.
-15-
<PAGE> 18
If the Depository for any Debt Securities represented by a Global Security
is at any time unwilling or unable to continue as Depository and a successor
Depository is not appointed by the Company within 90 days, the Company will
issue each Debt Security in definitive form to the beneficial owners thereof in
exchange for such Global Security. In addition, the Company may at any time and
in its sole discretion determine not to have any of the Debt Securities of a
series represented by one or more Global Securities and, in such event, will
issue Debt Securities of such series in definitive form in exchange for all of
the Global Security or Securities representing such Debt Securities.
The laws of some states require that certain purchasers of securities take
physical delivery of such securities in definitive form. Such laws may impair
the ability to transfer beneficial interests in Debt Securities represented by
Global Securities.
Governing Law. The Indenture and the Debt Securities will be governed by
and construed in accordance with the laws of the Commonwealth of Massachusetts.
DESCRIPTION OF SECURITIES WARRANTS
The Company may issue Securities Warrants for the purchase of Debt
Securities or Shares. Securities Warrants may be issued independently or
together with Debt Securities or Shares offered by any Prospectus Supplement and
may be attached to or separate from such Debt Securities or Shares. Each series
of Securities Warrants will be issued under a separate warrant agreement (a
"Securities Warrant Agreement") to be entered into between the Company and a
bank or trust company, as Securities Warrant agent, all as set forth in the
Prospectus Supplement relating to the particular issue of offered Securities
Warrants. The Securities Warrant agent will act solely as an agent of the
Company in connection with the Securities Warrant certificates relating to the
Securities Warrants and will not assume any obligation or relationship of agency
or trust for or with any holders of Securities Warrant certificates or
beneficial owners of Securities Warrants. The following summaries of certain
provisions of the Securities Warrant Agreement and Securities Warrants do not
purport to be complete and are subject to, and are qualified in their entirety
by reference to, all the provisions of the Securities Warrant Agreement and the
Securities Warrant certificates relating to each series of Security Warrants
which will be filed with the Commission and incorporated by reference as an
exhibit to the Registration Statement of which this Prospectus is a part at or
prior to the time of the issuance of such series of Security Warrants.
If Debt Securities Warrants are offered, the applicable Prospectus
Supplement will describe the terms of such Securities Warrants, including the
following where applicable: (i) the offering price, (ii) the denominations and
terms of the series of Debt Securities purchasable upon exercise of such
Securities Warrants, (iii) the designation and terms of any series of Debt
Securities with which such Securities Warrants are being offered and the number
of such
-16-
<PAGE> 19
Securities Warrants being offered with each such Debt Security, (iv) the date,
if any, on and after which such Securities Warrants and the related series of
Debt Securities will be transferable separately, (v) the principal amount of the
series of Debt Securities purchasable upon exercise of each such Securities
Warrant and the price at which such principal amount of Debt Securities of such
series may be purchased upon such exercise, (vi) the date on which the right to
exercise such Securities Warrants shall commence and the date (the "Expiration
Date") on which such right shall expire, (vii) whether the Securities Warrants
will be issued in registered or bearer form, (viii) any special United States
Federal income tax consequences, (ix) the terms, if any, on which the Company
may accelerate the Expiration Date and (x) any other terms of such Securities
Warrants.
In the case of Share Warrants, the applicable Prospectus Supplement will
describe the terms of such Securities Warrants, including the following where
applicable: (i) the offering price, (ii) the aggregate number of Shares
purchasable upon exercise of such Securities Warrants and the exercise price,
(iii) the designation and terms of the Securities with which such Securities
Warrants are being offered, if any, and the number of such Securities Warrants
being offered with each such Security, (iv) the date, if any, on and after which
such Securities Warrants and the related series of Debt Securities or Shares
will be transferable separately, (v) the date on which the right to exercise
such Securities Warrants shall commence and the Expiration Date, (vi) any
special United States Federal income tax consequences and (vii) any other terms
of such Securities Warrants.
Securities Warrant certificates may be exchanged for new Securities
Warrant certificates of different denominations, may (if in registered form) be
presented for registration of transfer, and may be exercised at the corporate
trust office of the Securities Warrant agent or any other office indicated in
the applicable Prospectus Supplement. Prior to the exercise of any Debt
Securities Warrants, holders of such Securities Warrants will not have any of
the rights of holders of the Debt Securities purchasable upon such exercise,
including the right to receive payments of principal of, premium, if any, or
interest, if any, on such Debt Securities or to enforce covenants in the
applicable indenture. Prior to the exercise of any Share Warrants, holders of
such Securities Warrants will not have any rights of holders of such Shares,
including the right to receive payments of dividends, if any, on such Shares, or
to exercise any applicable right to vote.
Certain Risk Considerations. Any Securities Warrants issued by the Company
will involve a certain degree of risk, including risks arising from the
fluctuations in the price of the underlying securities and general risks
applicable to the stock market (or markets) on which the underlying securities
are traded.
Prospective purchasers of the Securities Warrants should recognize that
the Securities Warrants may expire worthless and, thus, purchasers should be
prepared to sustain a total loss of the purchase price of their Securities
Warrants. This risk reflects the nature of a Securities
-17-
<PAGE> 20
Warrant as an asset which, other factors held constant, tends to decline in
value over time and which may, depending on the price of the underlying
securities, become worthless when it expires. The trading price of a Securities
Warrant at any time is expected to increase as the price, or, if applicable,
dividend rate on the underlying securities increases. Conversely, the trading
price of a Securities Warrant is expected to decrease as the time remaining to
expiration of the Securities Warrant decreases and as the price or, if
applicable, dividend rate on the underlying securities, decreases. Assuming all
other factors are held constant, the more a Securities Warrant is "out of the
money" (i.e., the more the exercise price exceeds the price of the underlying
securities and the shorter its remaining term to expiration), the greater the
risk that a purchaser of the Securities Warrant will lose all or part of his or
her investment. If the price of the underlying securities does not rise before
the Securities Warrant expires to an extent sufficient to cover a purchaser's
cost of the Securities Warrant, the purchaser will lose all or part of his or
her investment in such Securities Warrant upon expiration.
In addition, prospective purchasers of the Securities Warrants should be
experienced with respect to options and option transactions and understand the
risks associated with options and should reach an investment decision only after
careful consideration, with their financial advisers, of the suitability of the
Securities Warrants in light of their particular financial circumstances and the
information discussed herein and, if applicable, the Prospectus Supplement.
Before purchasing, exercising or selling any Securities Warrants, prospective
purchasers and holders of Securities Warrants should carefully consider, among
other things, (i) the trading price of the Securities Warrants, (ii) the price
of the underlying securities at such time, (iii) the time remaining to
expiration and (iv) any related transaction costs. Some of the factors referred
to above are in turn influenced by various political, economic and other factors
that can affect the trading prices of the underlying securities and should be
carefully considered prior to making any investment decisions.
Purchasers of the Securities Warrants should further consider that the
initial offering price of the Securities Warrants may be in excess of the price
that a purchaser of options might pay for a comparable option in a private, less
liquid transaction. In addition it is not possible to predict the price at which
the Securities Warrants will trade in the secondary market or whether any such
market will be liquid. The Company may, but is not obligated to, file an
application to list any Securities Warrants issued on a United States national
securities exchange. To the extent that any Securities Warrants are exercised,
the number of Securities Warrants outstanding will decrease, which may result in
a lessening of the liquidity of the Securities Warrants. Finally, the Securities
Warrants will constitute direct, unconditional and unsecured obligations of the
Company and as such will be subject to any changes in the perceived
creditworthiness of the Company.
Exercise of Securities Warrants. Each Securities Warrant will entitle the
holder thereof to purchase such principal amount of Debt Securities or number of
Shares, as the case may be, at such exercise price as shall in each case be set
forth in, or calculable from, the Prospectus
-18-
<PAGE> 21
Supplement relating to the offered Securities Warrants. After the close of
business on the Expiration Date (or such later date to which such Expiration
Date may be extended by the Company), unexercised Securities Warrants will
become void.
Securities Warrants may be exercised by delivering to the Securities
Warrant agent payment as provided in the applicable Prospectus Supplement of the
amount required to purchase the Debt Securities or Shares, as the case may be,
purchasable upon such exercise together with certain information set forth on
the reverse side of the Securities Warrant certificate. Securities Warrants will
be deemed to have been exercised upon receipt of payment of the exercise price,
subject to the receipt within five Business Days of the Securities Warrant
certificate evidencing such Securities Warrants. Upon receipt of such payment
and the Securities Warrant certificate properly completed and duly executed at
the corporate trust office of the Securities Warrant agent or any other office
indicated in the applicable Prospectus Supplement, the Company will, as soon as
practicable, issue and deliver the Debt Securities or Shares, as the case may
be, purchasable upon such exercise. If fewer than all of the Securities Warrants
represented by such Securities Warrant certificate are exercised, a new
Securities Warrant certificate will be issued for the remaining amount of
Securities Warrants.
Amendments and Supplements to Securities Warrant Agreement. The Securities
Warrant Agreements may be amended or supplemented without the consent of the
holders of the Securities Warrants issued thereunder, to effect changes that are
not inconsistent with the provisions of the Securities Warrants and that do not
adversely affect the interest of the holders of the Securities Warrants.
Share Warrant Adjustments. Unless otherwise indicated in the applicable
Prospectus Supplement, the exercise price of and the number of Shares covered by
a Share Warrant are subject to adjustment in certain events, including (i)
payment of a dividend on the Shares payable in Shares and Share splits,
combinations or reclassification of Shares, (ii) issuance to all holders of
Shares of rights or warrants to subscribe for or purchase Shares at less than
their current market price (as defined in the Securities Warrant Agreement for
such series of Share Warrants) and (iii) certain distributions of evidences of
indebtedness or assets (including securities but excluding cash, dividends or
distributions paid out of consolidated earnings or retained earnings or
dividends payable in Shares or of subscription rights and warrants excluding
those referred to above).
No adjustments in the exercise price of and the number of Shares covered
by a Share Warrant will be made for regular quarterly or other periodic or
recurring cash dividends or distributions or for cash dividends or distributions
to the extent paid from consolidated earnings or retained earnings. No
adjustment will be required unless such adjustment would require a change of at
least 1% in the exercise price then in effect. Except as stated above, the
exercise price of and the number of Shares covered by a Share Warrant will not
be adjusted for the issuance of Shares or any securities convertible into or
exchangeable for Shares or carrying the
-19-
<PAGE> 22
right or option to purchase or otherwise acquire the foregoing in exchange for
cash, other property or services.
In the event of any (i) consolidation or merger of the Company with or
into any entity (other than consolidation or a merger that does not result in
any reclassification, conversion, exchange or cancellation of outstanding
Shares), (ii) sale, transfer, lease or conveyance of all or substantially all of
the assets of the Company or (iii) reclassification, capital reorganization or
change of the Shares (other than solely a change in par value), then any holder
of a Share Warrant will be entitled, on or after the occurrence of any such
event, to receive on exercise of such Share Warrant the kind and amount of
Shares or other securities, cash or other property (or any combination thereof)
that the holder would have received had such holder exercised such holder's
Share Warrant immediately prior to the occurrence of such event. If the
consideration to be received upon exercise of the Share Warrant following any
such event consists of common stock (or its equivalent) of the surviving entity,
then from and after the occurrence of such event, the exercise price of such
Share Warrant will be subject to the same anti-dilution and other adjustments
described in the second preceding paragraph, applied as if such common stock
were Shares.
PLAN OF DISTRIBUTION
General.
The Company may sell the Securities in any of three ways: (i) through
underwriting syndicates represented by one or more managing underwriters, or by
one or more underwriters without a syndicate; (ii) through agents designated
from time to time; and (iii) directly to investors. The names of any
underwriters or agents of the Company involved in the sale of the Securities in
respect of which this Prospectus is being delivered and any applicable
commissions or discounts will be set forth in the Prospectus Supplement. The net
proceeds to the Company from such sale will also be set forth in the Prospectus
Supplement.
The distribution of the Securities may be effected from time to time in
one or more transactions at a fixed price or prices (which may be changed from
time to time), at market prices prevailing at the time of sale, at prices
related to such prevailing market prices or at negotiated prices. The Prospectus
Supplement will describe the method of distribution of the Securities.
In connection with the sale of Securities, underwriters or agents acting
on the Company's behalf may receive compensation from the Company or from
purchasers of Securities for whom they may act as agents, in the form of
discounts, concessions or commissions. The underwriter, dealers and agents that
participate in the distribution of Securities may be deemed to be underwriters
under the Securities Act and any discounts or commissions received by them
-20-
<PAGE> 23
and any profit on the resale of Securities by them may be deemed to be
underwriting discounts and commissions under the Securities Act. Any such
underwriter will be identified and any such compensation will be described in
the Prospectus Supplement.
Agents and underwriters may be entitled under agreements entered into with
the Company to indemnification by the Company against certain liabilities,
including liabilities under the Securities Act, or to contribution with respect
to payments which the agents or underwriters may be required to make in respect
thereof. Agents and underwriters may engage in transactions with or perform
services for the Company in the ordinary course of business.
Structured Equity Program.
The Company may also issue and sell Shares from time to time through one
or more sales agents (to be named in a prospectus supplement hereto, the
"Agent") in ordinary brokers' transactions on the New York Stock Exchange (the
"NYSE"). Such sales, if any, will be effected during a series of one or more
pricing periods (each, a "Pricing Period"), each consisting of five consecutive
calendar days in duration, unless a shorter period has otherwise been agreed to
by the Company and the Agent. For each Pricing Period, an Average Market Price
(as hereinafter defined) will be computed. With respect to any Pricing Period,
"Average Market Price" shall equal the average of the arithmetic mean of the
high and low sales prices of the Shares of the Company reported on the NYSE for
each trading day of such Pricing Period.
The net proceeds to the Company with respect to sales of Shares in any
Pricing Period up to a maximum amount agreed to in advance with the Agent (the
"Average Market Price Shares") will equal a percentage (the "Company's
Percentage") of the Average Market Price for each Share sold during the Pricing
Period (subject to adjustment in certain circumstances), plus Excess Proceeds
(as defined below), if any. The compensation to the Agent for sales of Average
Market Price Shares in any Pricing Period will equal the difference between the
aggregate gross sales price at which such sales are actually effected and the
net proceeds to the Company for such sales, but in no event will exceed 10% of
the aggregate gross sales prices of the Average Market Price Shares during any
Pricing Period (the "Maximum Commission"). To the extent that such aggregate
gross sales prices are less than the Average Market Price, the compensation to
the Agent will be correspondingly reduced; to the extent that such aggregate
gross sales prices are greater than the Average Market Price, the compensation
to the Agent will be correspondingly increased (but in no event will exceed the
Maximum Commission). In the event that the average aggregate gross sales price
in any Pricing Period equals the Company's Percentage of the Average Market
Price (or less) for such Pricing Period, all of the proceeds from such sales
will be for the account of the Company and no compensation will be payable to
the Agent. To the extent that the Agent's compensation under the foregoing
formula would otherwise exceed the Maximum Commission in any Pricing Period, the
excess will constitute additional net proceeds to the Company (the "Excess
Proceeds").
-21-
<PAGE> 24
Any Shares sold by the Agent during the Pricing Period on behalf of the
Company other than Average Market Price Shares ("Additional Shares") will be at
a fixed commission rate based on a percentage of the Share price per Share. In
no event will the compensation to the Agent be in excess of any applicable
requirements of the National Association of Securities Dealers, Inc.
Settlements of sales of Additional Shares and Average Market Price Shares
will occur on the third business day following the date on which any such sales
are made. Purchases of Shares from the Agent, as sales agent for the Company,
will settle the regular way on the NYSE. Compensation to the Agent with respect
to sales of Average Market Price Shares will be paid out of the proceeds of such
settlements. There is no arrangement for funds to be received in an escrow,
trust or similar arrangement.
At the end of each Pricing Period, the Company will file a Prospectus
Supplement under the applicable paragraph of Rule 424(b) promulgated under the
Act, which Prospectus Supplement will set forth the name of the Agent, dates
included in such Pricing Period, the number of such Shares sold through the
Agent as sales agent (identifying separately the number of Average Market Shares
and any Additional Shares), the high and low prices at which Average Market
Shares were sold during such Pricing Period, the net proceeds to the Company,
the compensation payable by the Company to the Agent with respect to such sales
pursuant to the formula set forth above and other relevant information. Unless
otherwise indicated in a Prospectus Supplement, the Agent will act as sales
agent on a best efforts basis.
In connection with the sale of the Shares on behalf of the Company, the
Agent may be deemed to be an "underwriter" within the meaning of the Securities
Act, and the compensation of the Agent may be deemed to be underwriting
commissions or discounts. The Company intends to provide indemnification and
contribution to the Agent against certain civil liabilities, including
liabilities under the Securities Act. The Agent may engage in transactions with,
or perform services for, the Company in the ordinary course of business.
LEGAL MATTERS
The validity of the Securities offered hereby will be passed upon for the
Company by Nutter, McClennen & Fish, Boston, Massachusetts. In addition, Nutter,
McClennen & Fish will pass upon certain Federal income tax matters relating to
the Company. The name of any legal counsel that passes on the validity of the
other Securities offered hereby for any underwriter or agent will be set forth
in the applicable Prospectus Supplement.
-22-
<PAGE> 25
EXPERTS
The consolidated balance sheets of the Company as of December 31, 1994 and
1993 and the related consolidated statements of income, changes in shareholders'
equity and cash flows for each of the three years in the period ended December
31, 1994, and the financial statement schedules incorporated by reference in
this Prospectus and elsewhere in the Registration Statement, have been audited
by Coopers & Lybrand L.L.P., independent accountants, as indicated in their
report with respect thereto, and are incorporated by reference herein in
reliance upon the authority of said firm as experts in accounting and auditing.
Any financial statements and schedules hereafter incorporated by reference in
the registration statement of which this Prospectus is a part that have been
audited and are the subject of a report by independent accountants will be so
incorporated by reference in reliance upon such reports and upon the authority
of such firms as experts in accounting and auditing to the extent covered by
consents filed with the Commission.
-23-
<PAGE> 26
- --------------------------------------------------------------------------------
NO DEALER, SALESPERSON OR OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATIONS, OTHER THAN THOSE HEREIN, IN
CONNECTION WITH THIS OFFERING AND, IF GIVEN OR MADE, SUCH INFORMATION OR
REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY
OR ANY OTHER PERSON. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL, OR
SOLICITATION OF AN OFFER TO BUY, ANY OF THE SECURITIES IN ANY JURISDICTION TO
ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION IN SUCH
JURISDICTION. THE DELIVERY OF THIS PROSPECTUS AT ANY TIME DOES NOT IMPLY THAT
THE INFORMATION IN THE PROSPECTUS IS CORRECT AS OF ANY TIME SUBSEQUENT TO ITS
DATE.
- --------------------------------------------------------------------------------
<TABLE>
TABLE OF CONTENTS
<CAPTION>
Page
----
<S> <C>
Available Information .................................................. 2
Incorporation of Certain
Documents by Reference ............................................... 2
The Company ............................................................ 4
Health Care Reform
and Regulation ........................................................ 6
Ratio of Earnings to Fixed
Charges .............................................................. 6
Use of Proceeds ........................................................ 6
Description of Shares .................................................. 7
Description of Debt
Securities ........................................................... 9
Description of Securities
Warrants ............................................................. 16
Plan of Distribution ................................................... 20
Legal Matters .......................................................... 23
Experts ................................................................ 23
</TABLE>
- --------------------------------------------------------------------------------
MEDITRUST
PROSPECTUS
August 31, 1995
- --------------------------------------------------------------------------------
<PAGE> 27
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
<TABLE>
Item 14. Other Expenses of Issuance and Distribution
Set forth below is an estimate of the amount of fees and expenses to be
incurred in connection with the issuance and distribution of the Securities
registered hereby.
<S> <C>
Securities and Exchange Commission Registration Fee...................................... $103,448
New York Stock Exchange Listing Fees..................................................... 15,000
Blue Sky Fees and Expenses (including legal fees)........................................ 10,000
Legal Fees and Expenses.................................................................. 100,000
Accounting Fees.......................................................................... 25,000
Printing and Engraving................................................................... 75,000
Trustee Fees............................................................................. 25,000
Miscellaneous Expenses................................................................... 46,552
--------
Total............................................................................... $400,000
========
</TABLE>
Item 15. Indemnification of Directors and Officers
The Company's Declaration of Trust provides for indemnification of the
Company's Trustees and officers against expense or liability in any action
arising out of such persons' activities on behalf of the Company, except to the
extent arising from his or her own misconduct or negligence.
The forms of Underwriting Agreements, Distribution Agreement, Placement
Agency Agreement and Sales Agency Agreement (Exhibits 1.1, 1.2, 1.3, 1.4 and 1.5
hereto) provide for indemnification by the Underwriters, Agents and Placement
Agents of the Company and its Trustees, officers and controlling persons under
certain circumstances.
The Company currently maintains director and officer liability
insurance which protects its Trustees and officers against certain liabilities
incurred in serving in such capacities with specific exceptions.
Item 16. Exhibits
The following is a list of exhibits filed as part of this Registration Statement
(numbering corresponds to numbering in Item 601 of Regulation S-K).
II-1
<PAGE> 28
<TABLE>
<CAPTION>
Exhibit Description
No.
- -------
<S> <C>
1.1 Form of Underwriting Agreement (incorporated by reference to
Exhibit 1 to the Current Report on Form 8-K dated October 7,
1994)
1.2 Form of Underwriting Agreement (incorporated by reference to
Exhibit 1 to the Current Report on Form 8-K dated July 13,
1995)
1.3 Form of Distribution Agreement (incorporated by reference to
Exhibit 1 to the Current Report dated August 8, 1995)
1.4 Form of Placement Agency Agreement (incorporated by reference
to Exhibit 1.1 to the Registration Statement on Form S-3 (File
No. 33-55386))
1.5 Form of Sales Agency Agreement.
4.1 Restated Declaration of Trust, as amended (incorporated by
reference to Exhibit 3.1 to the Current Report on Form 8-K
dated July 21, 1994)
4.2 By-laws, as amended (incorporated by reference to Exhibit 3.2
to the Annual Report on Form 10-K for the fiscal year ended
December 31, 1992)
4.3 Form of Indenture and Form of Convertible Debenture
(incorporated by reference to Exhibit 4 to the Registration
Statement on Form S-3 (File No. 33-50835))
4.4 Form of Indenture Supplement and Form of Note (incorporated by
reference to Exhibit 4.1 to the Current Report on Form 8-K
dated July 13, 1995)
4.5 Form of Indenture Supplement and Forms of Convertible Notes
(incorporated by reference to Exhibit 4.1 to the Current
Report on Form 8-K dated July 27, 1995)
4.6 Form of Indenture Supplement and Forms of Medium-Term Notes
(incorporated by reference to Exhibit 4.1 to the Current
Report on Form 8-K dated August 13, 1995)
4.7 Form of Debt Security(1)
4.8 Form of Securities Warrant Agreement(1)
<FN>
- -------------------
(1) To be filed by amendment or incorporated by reference if
necessary in connection with the offering of the Securities.
</TABLE>
II-2
<PAGE> 29
<TABLE>
<S> <C>
5 Opinion letter of Nutter, McClennen & Fish
8 Opinion letter of Nutter, McClennen & Fish regarding tax
matters
12 Computation of Ratios of Earnings to Fixed Charges
23.1 Consents of Nutter, McClennen & Fish (included in Exhibits 5
and 8)
23.2 Consent of Coopers & Lybrand L.L.P.
25 Form T-1 Statement of Eligibility and Qualification of Fleet
National Bank under the Trust Indenture Act of 1939
</TABLE>
Item 17. Undertakings.
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after
the effective date of this registration statement (or the most
recent post-effective amendment thereof) which, individually
or in the aggregate, represent a fundamental change in the
information set forth in this registration statement; and
(iii) To include any material information with respect to the plan
of distribution not previously disclosed in this registration
statement or any material change to such information in this
registration statement;
provided, however, that subparagraphs (i) and (ii) do not apply if the
registration statement is on Form S-3 or Form S-8, and the information
required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed by the registrant
pursuant to Section 13 or Section 15(d) of the Securities Exchange Act
of 1934 that are incorporated by reference in this registration
statement;
(2) That, for the purpose of determining any liability under the Securities
Act of 1933, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein,
and the offering of such
II-3
<PAGE> 30
securities at that time shall be deemed to be the initial bona fide
offering thereof; and
(3) To remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the
termination of the offering.
(b) The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an
employee benefit plan's annual report pursuant to Section 15(d) of the
Securities Exchange Act of 1934) that is incorporated by reference in this
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
(c) The undersigned registrant hereby undertakes that for purposes of
determining any liability under the Securities Act of 1933, the information
omitted from the form of prospectus filed as part of this registration statement
in reliance upon Rule 430A and contained in the form of prospectus filed by the
registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act
shall be deemed to be part of this registration statement as of the time it was
declared effective.
(d) The undersigned registrant hereby undertakes that for the purpose of
determining any liability under the Securities Act of 1933, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(e) Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to trustees, officers and controlling persons of the
registrant pursuant to the provisions of the registrant's Restated Declaration
of Trust, as amended, By-laws, as amended, the agreements described under Item
15 of this Registration Statement or otherwise, the registrant has been advised
that, in the opinion of the Securities and Exchange Commission, such
indemnification is against public policy as expressed in the Securities Act of
1933 and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or a controlling
person of the registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy, as expressed in the Securities
Act of 1933, and will be governed by the final adjudication of such issue.
II-4
<PAGE> 31
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the Town of Needham, Commonwealth of Massachusetts on August 31,
1995.
MEDITRUST
By: /s/ Abraham D. Gosman
-------------------------------
Abraham D. Gosman, Chairman of
the Board and Chief Executive
Officer
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints Abraham D. Gosman, David F. Benson, Michael S.
Benjamin, Michael J. Bohnen and Paul R. Eklund, and each of them singly, his
attorneys-in-fact and agents, each with full power of substitution, for him in
any and all capacities, to sign this registration statement and any amendments
hereto, and to file the same, with exhibits thereto, and other documents in
connection therewith, with the Securities and Exchange Commission and any other
regulatory authority or body, granting unto each said attorney-in-fact and agent
full power and authority to do and perform each and every act and thing
requisite and necessary to be done in connection with this registration
statement, as fully as he might or could do in person, hereby ratifying and
confirming all that each said attorney-in-fact and agent, or his substitute or
substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this
registration statement has been signed below by the following persons on behalf
of the registrant in the capacities and on the dates indicated.
<TABLE>
<CAPTION>
Signature Title Date
- --------- ----- ----
<S> <C> <C>
/s/ Abraham D. Gosman Chairman of the
- -------------------------
Abraham D. Gosman Board and Chief
(Principal Executive Officer) Executive Officer August 31, 1995
/s/ Lisa P. McAlister Treasurer and
- -------------------------
Lisa P. McAlister (Principal Vice President
Financial and Accounting Officer) August 31, 1995
</TABLE>
II-5
<PAGE> 32
<TABLE>
<S> <C> <C>
/s/ David F. Benson President
- ----------------------------
David F. Benson and Trustee August 31, 1995
/s/ Edward W. Brooke Trustee August 31, 1995
- ----------------------------
Edward W. Brooke
Trustee August , 1995
- ----------------------------
Hugh L. Carey
/s/ Robert Cataldo Trustee August 31, 1995
- ----------------------------
Robert Cataldo
/s/ Philip L. Lowe Trustee August 31, 1995
- ----------------------------
Philip L. Lowe
Trustee August , 1995
- ----------------------------
Thomas J. Magovern
/s/ Gerald Tsai, Jr. Trustee August 31, 1995
- ----------------------------
Gerald Tsai, Jr.
Trustee August , 1995
- ----------------------------
Frederick W. Zuckerman
</TABLE>
II-6
<PAGE> 1
EXHIBIT 1.5
MEDITRUST
Shares of Beneficial Interest
without par value
SALES AGENCY AGREEMENT
____________, 1995
[Name and Address of Agent]
Gentlemen:
Meditrust, a Massachusetts business trust (the "Company"), confirms its
agreement with _____________ (the "Agent"), as follows:
SECTION 1. Description of Securities. The Company proposes to issue and
sell through the Agent, as exclusive sales agent, up to ___________ shares (the
"Maximum Amount") of beneficial interest, without par value (the "Stock"), on
the terms set forth in Section 3 hereof.
SECTION 2. Representations and Warranties of the Company. The Company
represents and warrants to, and agrees with, the Agent that:
(a) The Company meets the requirements for use of Form S-3 under the
Securities Act of 1933 (the "Act") and the rules and regulations ("Rules and
Regulations") of the Securities and Exchange Commission (the "Commission"). A
registration statement on Form S-3 (Registration No. 33-_____) with respect to,
among other securities, the Stock, including a form of prospectus, has been
prepared by the Company in conformity with the requirements of the Act and the
Rules and Regulations thereunder and filed with the Commission and has become
effective. Such registration statement and prospectus may have been amended or
supplemented prior to the date of this Agreement. Any such amendment or
supplement was so prepared and filed, and any such amendment or supplement filed
after the effective date of such registration statement has become effective. No
stop order suspending the effectiveness of the registration statement has been
issued, and no proceeding for that purpose has been instituted or threatened by
the Commission. Copies of such registration statement and prospectus, any such
amendment or supplement relating to the Stock and all documents incorporated by
reference therein that were filed with the Commission on or prior to the date of
this Agreement have been delivered to the Agent. Such registration statement, as
it may have heretofore been amended, is referred to herein as the "Registration
Statement," and the final form of prospectus included in the Registration
Statement, as amended or
<PAGE> 2
supplemented from time to time, is referred to herein as the "Prospectus." Any
reference herein to the Registration Statement, the Prospectus, or any amendment
or supplement thereto shall be deemed to refer to and include the documents
incorporated (or deemed to be incorporated) by reference therein, and any
reference herein to the terms "amend," "amendment" or "supplement" with respect
to the Registration Statement or Prospectus shall be deemed to refer to and
include the filing after the date hereof of any document with the Commission
deemed to be incorporated by reference therein.
(b) Each part of the Registration Statement, when such part became or
becomes effective, and the Prospectus and any amendment or supplement thereto,
on the date of filing thereof with the Commission and at each Closing Date (as
hereinafter defined), conformed or will conform in all material respects with
the requirements of the Act and the Rules and Regulations; each part of the
Registration Statement, when such part became or becomes effective, did not or
will not contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements
therein not misleading; and the Prospectus and any amendment or supplement
thereto, on the date of filing thereof with the Commission and at each Closing
Date, did not or will not include an untrue statement of a material fact or omit
to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading; except that the
foregoing shall not apply to statements in or omissions from any such document
in reliance upon, and in conformity with, written information furnished to the
Company by or on behalf of the Agent, specifically for use in the Registration
Statement, the Prospectus or any amendment or supplement thereto.
(c) The documents incorporated by reference in the Registration
Statement or the Prospectus, or any amendment or supplement thereto, when they
became or become effective under the Act or were or are filed with the
Commission under the Securities Exchange Act of 1934, as amended ("Exchange
Act"), as the case may be, conformed or will conform in all material respects
with the requirements of the Act or the Exchange Act, as applicable, and the
rules and regulations of the Commission thereunder.
(d) The financial statements of the Company and its subsidiaries,
together with the related notes and schedules, set forth or incorporated by
reference in the Registration Statement and Prospectus fairly present the
financial condition and the results of operations and cash flows of the Company
and its subsidiaries as of the dates indicated or for the periods therein
specified and were prepared in conformity with generally accepted accounting
principles consistently applied throughout the periods involved (except as
otherwise stated therein).
-2-
<PAGE> 3
(e) The Company has been duly organized and is validly existing as a
business trust in good standing under the laws of the Commonwealth of
Massachusetts with power and authority to own, lease and operate its properties
and to conduct its business as described in the Registration Statement and
Prospectus; and the Company is duly qualified as a foreign corporation to
transact business and is in good standing in each jurisdiction in which such
qualification is required, whether by reason of the ownership or leasing of
property or the conduct of business, except where the failure to so qualify and
be in good standing would not have a material adverse effect on the condition,
financial or otherwise, or the earnings, business affairs or business prospects
of the Company and its subsidiaries considered as one enterprise.
(f) Each subsidiary of the Company (the "Subsidiaries") has been duly
incorporated and is validly existing as a corporation or limited partnership in
good standing under the laws of the jurisdiction of its incorporation, has
corporate power and authority to own, lease and operate its properties and
conduct its business as described in the Registration Statement and Prospectus
and is duly qualified as a foreign corporation or limited partnership to
transact business and is in good standing in each jurisdiction in which such
qualification is required, whether by reason of the ownership or leasing of
property or the conduct of business, except where the failure to so qualify and
be in good standing would not have a material adverse effect on the condition,
financial or otherwise, or the earnings, business affairs or business prospects
of the Company and its subsidiaries considered as one enterprise; and all of the
issued and outstanding capital stock of each corporate Subsidiary has been duly
authorized and validly issued, is fully paid and nonassessable and (except as
otherwise stated in the Registration Statement) is owned by the Company,
directly or through subsidiaries, free and clear of any security interest,
mortgage, pledge, lien, encumbrance, claim or equity.
(g) The outstanding shares of beneficial interest of the Company and
the Stock have been duly authorized and are, or when issued as contemplated
hereby will be, validly issued, fully paid and nonassessable and conform, or
when so issued will conform, to the description thereof in the Prospectus. The
shareholders of the Company have no preemptive rights with respect to the Stock.
(h) Except as contemplated in the Prospectus, subsequent to the
respective dates as of which information is given in the Registration Statement
and the Prospectus, neither the Company nor any of its Subsidiaries has incurred
any liabilities or obligations, direct or contingent, or entered into any
transactions, not in the ordinary course of business, that are material to the
Company and its Subsidiaries considered as a whole, and there has not been any
material change in the capital
-3-
<PAGE> 4
stock, short-term debt or long-term debt of the Company and its Subsidiaries, or
any material change, or any development involving a prospective material change,
in the condition, financial or otherwise, or the earnings, business affairs or
business prospects of the Company and its Subsidiaries considered as one
enterprise.
(i) Except as set forth in the Prospectus, there is not pending or, to
the knowledge of the Company, threatened any action, suit or proceeding to which
the Company or any of its Subsidiaries is a party, before or by any court or
governmental agency or body, that could reasonably be expected to result in any
material adverse change in the condition, financial or otherwise, or the
earnings, business affairs or business prospects of the Company and its
subsidiaries considered as one enterprise, or that could reasonably be expected
to materially and adversely affect the properties or assets thereof considered
as a whole.
(j) There are no contracts or documents of the Company or any of its
Subsidiaries that are required to be filed as exhibits to the Registration
Statement or to any of the documents incorporated by reference therein by the
Act or the Exchange Act or by the rules and regulations of the Commission
thereunder that have not been so filed.
(k) All necessary action has been duly and validly taken by the Company
to authorize the execution, delivery and performance of this Agreement. This
Agreement has been duly and validly authorized, executed and delivered by the
Company and constitutes the legal, valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms, except as the
enforceability thereof may be limited by bankruptcy, insolvency, reorganization,
moratorium or other similar laws affecting the enforcement of creditors' rights
generally and by general equitable principles.
(l) The performance of this Agreement and the consummation of the
transactions contemplated herein or therein will not result in a breach or
violation of any of the terms and provisions of, or constitute a default under,
any statute, any agreement or instrument to which the Company or any of its
Subsidiaries is a party or by which it is bound or to which any of the property
of the Company or any of its Subsidiaries is subject, the Company s charter or
by-laws, or any order, rule or regulation of any court or governmental agency or
body having jurisdiction over the Company or any of its Subsidiaries or any of
its properties; no consent, approval, authorization or order of, or filing with,
any court or governmental agency or body is required for the consummation by the
Company of the transactions contemplated by this Agreement, except such as have
been obtained
-4-
<PAGE> 5
or completed or as may be required by state securities or blue sky laws.
(m) Each of the Company and its Subsidiaries has (i) good and
marketable title to all of the properties and assets described in the Prospectus
as owned by it, free and clear of all liens, charges, encumbrances or
restrictions, except such as are described in the Prospectus or are not material
to the business, condition, financial or otherwise, or the earnings, business
affairs or business prospects of the Company and its subsidiaries considered as
one enterprise, (ii) peaceful and undisturbed possession under all leases to
which it is party as lessee, (iii) all governmental or regulatory licenses,
certificates, permits, authorizations, approvals, franchises or other rights
necessary to engage in the business currently conducted by it, except such as
are not material to the business, condition, financial or otherwise, or the
earnings, business affairs or business prospects of the Company and its
subsidiaries considered as one enterprise, (iv) no reason to believe that any
governmental body or agency is considering limiting, suspending or revoking any
such license, certificate, permit, authorization, approval, franchise or right
and (v) not received any notice of and has no reason to believe that any
governmental body or agency is considering enacting, amending or repealing any
statute, law, ordinance or regulation required to be described in the
Registration Statement and Prospectus that is not so described as required. All
material leases to which the Company or any of its Subsidiaries is a party are
valid and binding and no default has occurred and is continuing thereunder, and,
to the best knowledge of the Company, no material defaults by the landlord are
existing under any such leases.
(n) Each of the Company and its Subsidiaries owns or possesses all of
the patents, patent rights, licenses, inventions, copyrights, know-how
(including trade secrets and other unpatented and/or unpatentable proprietary or
confidential information, systems or procedures), trademarks, service marks and
trade names presently employed by them in connection with the business now
operated by them, and neither the Company nor any of its Subsidiaries has
received any notice of infringement of or conflict with asserted rights of
others with respect to any of the foregoing which, if singly or in the
aggregate, if the subject of an unfavorable decision, ruling or finding, would
result in any material adverse change in the condition, financial or otherwise,
or in the earnings, business affairs or business prospects of the Company and
its subsidiaries considered as one enterprise.
(o) The Company and its Subsidiaries have not violated and are in
compliance with all material laws, statutes, ordinances, regulations, rules and
orders of any foreign, federal, state or local government and any other
governmental department or agency,
-5-
<PAGE> 6
and any judgment, decision, decree or order of any court or governmental agency,
department or authority, including, without limitation, environmental laws.
Neither the Company nor any of its Subsidiaries has received any notice to the
effect that, or otherwise been advised that, it is not in compliance with any
such statutes, regulations, rules, judgments, decrees, orders, ordinances or
other laws, and the Company is not aware of any existing circumstances which are
likely to result in violations of any of the foregoing.
SECTION 3. Sale and Delivery of Securities. On the basis of the
representations, warranties and agreements herein contained, but subject to the
terms and conditions herein set forth, the Company agrees to issue and sell
exclusively through the Agent, and the Agent agrees to sell, as exclusive sales
agent for the Company, on a best efforts basis, up to the Maximum Amount of
Stock during 52 Pricing Periods (as hereinafter defined) on the terms set forth
herein.
The Stock, up to the Maximum Amount, is to be sold during one or more
pricing periods (each a "Pricing Period"), each Pricing Period consisting of
five consecutive calendar days or such lesser number of days as shall be agreed
to by the Company and the Agent. The Company and the Agent from time to time
will designate Pricing Period(s) and the number of shares of Stock (not to
exceed ____ shares) to be sold by the Agent during each such Pricing Period (the
"Average Market Price Shares"). Subject to the terms and conditions hereof, the
Agent shall use its best efforts to (i) sell all of the designated Average
Market Price Shares during each such Pricing Period, and (ii) sell the entire
Maximum Amount. The Agent shall sell the shares of Stock only by means of
ordinary brokers transactions on the New York Stock Exchange (the "NYSE"). The
Agent shall not solicit or arrange for the solicitation of customers' orders in
anticipation of or in connection with such transactions, nor shall they sell
short as principal shares of Stock of the Company except in connection with
customary market making activities in the Company's outstanding securities. The
Agent shall not engage in any special selling efforts or selling methods
relating to the Stock within the meaning of Rule 10b-6(c)(5) under the Exchange
Act. The Company or the Agent may, upon notice to the other party hereto by
telephone (confirmed promptly by telecopy), suspend or terminate the offering of
Stock during any Pricing Period; provided, however, that such suspension or
termination shall not affect or impair the parties respective obligations with
respect to shares of Stock sold hereunder prior to the giving of such notice.
The net proceeds (the "Net Proceeds") to the Company for the Average
Market Price Shares sold by the Agent during a Pricing Period will equal the sum
of (i) the product of (x) ___% times (y) the average of the arithmetic mean of
the high and low sales
-6-
<PAGE> 7
prices of the shares of beneficial interest of the Company reported on the NYSE
for each trading day of such Pricing Period (the "Average Market Price"), times
(z) the number of Average Market Price Shares sold during such Pricing Period
plus (ii) Alternative Proceeds (defined below), if any, plus (iii) Excess
Proceeds (defined below), if any. Subject to adjustment as set forth in the
following two paragraphs, the compensation to the Agent with respect to the sale
of Average Market Price Shares sold hereunder shall equal the difference between
the aggregate gross sales prices at which such sales are actually effected by
the Agent and the Net Proceeds.
To the extent that the compensation payable to the Agent hereunder
would otherwise exceed ten percent of the aggregate gross sales prices of the
Average Market Price Shares during any Pricing Period, such excess over ten
percent shall constitute "Excess Proceeds" payable to the Company.
During any Pricing Period, the Company may instruct the Agent by
telephone (confirmed promptly by telecopy) not to sell shares of Stock if such
sales cannot be effected at or above the price designated by the Company in any
such instruction. If such an instruction is given and as a result thereof the
Agent is unable to sell shares of Stock in an amount greater than or equal to
the daily pro rata portion of Average Market Price Shares to be sold during such
Pricing Period, then (i) that day's high and low executed sales price of shares
of beneficial interest of the Company reported on the NYSE shall not be included
in the calculation of Average Market Price and (ii) the net proceeds payable to
the Company (the "Alternative Proceeds") and the compensation payable to the
Agent in respect of any sales of Average Market Price Shares effected that day
(the "Alternative Shares") by the Agent shall be equal to ___% and ___%,
respectively, of the weighted average sales prices at which the Agent has
actually effected sales of Stock during that day and the Alternative Shares
shall not be deemed to be Average Market Price Shares sold during a Pricing
Period.
During any Pricing Period, the Company and the Agent may agree upon the
sale of shares ("Additional Shares") of Stock in addition to the sale of Average
Market Price Shares (such Additional Shares to be included in the Maximum
Amount). The compensation to the Agent for sales of Additional Shares shall be,
with respect to any Pricing Period, ___% of the gross sales price per share in
connection with Additional Shares in any Pricing Period. The sale of Additional
Shares sold during any day shall be confirmed in writing by the Agent to the
Company following the end of the Pricing Period. All other shares sold during a
Pricing Period not so confirmed shall be deemed Average Market Price Shares.
-7-
<PAGE> 8
The Agent shall provide written confirmation to the Company following
the close of business on the final day of each Pricing Period setting forth,
with regard to such Pricing Period, the dates included in the Pricing Period,
the number of Average Market Price Shares and Additional Shares, if any, sold,
the gross proceeds from the sale of such shares, the highest and lowest executed
sales price at which such shares were sold, the Net Proceeds to the Company, the
amount of Excess Proceeds, if any, the amount of Alternative Proceeds, if any,
the compensation payable by the Company to the Agent with respect to such sales
and the Average Market Price for such Pricing Period.
Settlement for sales of Additional Shares will occur on the third
business day following the date on which such sales are made. The amount of
proceeds for such sales to be delivered to the Company against the receipt of
the Additional Shares sold shall be equal to the aggregate sales prices at which
such Additional Shares were sold, net of the Agent's compensation for such sales
and after deduction for any transaction fees imposed by any governmental or
self-regulatory organization in respect of such sales. Settlement for sales of
Average Market Price Shares will also occur on the third business day following
the date on which such sales are made. On the third business day following the
end of a Pricing Period, the Average Market Price Shares sold through the Agent
on the last business day of such Pricing Period will be delivered by the Company
to the Agent against payment of the proceeds for the sale of such Average Market
Price Shares less the total compensation to the Agent for the sale of Average
Market Price Shares for such Pricing Period. Settlement for all shares shall be
effected via The Depository Trust Company on a delivery-versus-payment basis.
At the time of each settlement of securities hereunder, the Company
shall be deemed to have affirmed each representation, warranty, covenant and
other agreement contained in this Agreement and on each Closing Date, the
Company shall affirm in writing each representation, warranty, covenant and
other agreement contained in this Agreement. The Company covenants and agrees
with the Agent that within two (2) business days of the termination of each
Pricing Period, the Company will file a prospectus supplement under the
applicable paragraph of Rule 424(b) under the Act, which prospectus supplement
will set forth, with regard to such Pricing Period, the dates included within
the Pricing Period, the number of shares of Stock sold through the Agent
(separately identifying the number of Average Market Price Shares), the high and
low prices at which Average Market Price Shares were sold, the Net Proceeds to
the Company and the compensation payable by the Company to the Agent with
respect to sales of Average Market Price Shares (all as provided in writing by
the Agent for inclusion in each such prospectus supplement). Any obligation of
the Agent to use its best efforts to sell the Stock shall be subject to the
continuing accuracy of
-8-
<PAGE> 9
the representations and warranties of the Company herein, to the performance by
the Company of its obligations hereunder and to the continuing satisfaction of
the additional conditions specified in Section 5 of this Agreement.
SECTION 4. Covenants of the Company. The Company covenants and agrees
with the Agent that:
(a) During the period in which a prospectus relating to the Stock is
required to be delivered under the Act, the Company will notify the Agent
promptly of the time when any subsequent amendment to the Registration Statement
has become effective or any subsequent supplement to the Prospectus has been
filed and of any request by the Commission for any amendment or supplement to
the Registration Statement or Prospectus or for additional information; the
Company will not file any amendment or supplement to the Registration Statement
or Prospectus (other than any prospectus supplement relating to the offering of
other securities registered under the Registration Statement) unless a copy
thereof has been submitted to you a reasonable period of time before the filing
and you have not reasonably objected thereto; and it will furnish to the Agent
prior to the filing thereof a copy of any document that upon filing is deemed to
be incorporated by reference in the Registration Statement or Prospectus; and
the Company will cause each amendment or supplement to the Prospectus to be
filed with the Commission as required pursuant to the applicable paragraph of
Rule 424(b) of the Rules and Regulations or, in the case of any document to be
incorporated therein by reference, to be filed with the Commission as required
pursuant to the Exchange Act, within the time period prescribed.
(b) The Company will advise the Agent, promptly after it shall receive
notice or obtain knowledge thereof, of the issuance by the Commission of any
stop order suspending the effectiveness of the Registration Statement, of the
suspension of the qualification of the Stock for offering or sale in any
jurisdiction, or of the initiation or threatened initiation of any proceeding
for any such purpose; and it will promptly use its best efforts to prevent the
issuance of any stop order or to obtain its withdrawal if such a stop order
should be issued.
(c) Within the time during which a prospectus relating to the Stock is
required to be delivered under the Act, the Company will comply as far as it is
able with all requirements imposed upon it by the Act and by the Rules and
Regulations, as from time to time in force, so far as reasonably necessary to
permit the continuance of sales of or dealings in the Stock as contemplated by
the provisions hereof and the Prospectus. If during such period any event occurs
as a result of which the Prospectus as then amended or supplemented would
include an untrue statement of a material fact or omit to state a material fact
necessary to
-9-
<PAGE> 10
make the statements therein, in the light of the circumstances then existing,
not misleading, or if during such period it is necessary to amend or supplement
the Registration Statement or Prospectus to comply with the Act, the Company
will promptly notify the Agent to suspend the offering of Stock during such
period and the Company will amend or supplement the Registration Statement or
Prospectus (at the expense of the Company) so as to correct such statement or
omission or effect such compliance.
(d) The Company will use its best efforts to qualify the Stock for sale
under the securities laws of such jurisdictions as the Agent designates and to
continue such qualifications in effect so long as required for the distribution
of the Stock, except that the Company shall not be required in connection
therewith to qualify as a foreign entity or to execute a general consent to
service of process in any jurisdiction.
(e) The Company will furnish to the Agent and its counsel (at the
expense of the Company) copies of the Registration Statement, the Prospectus
(including all documents incorporated by reference therein) and all amendments
and supplements to the Registration Statement or Prospectus that are filed with
the Commission during the period in which a prospectus relating to the Stock is
required to be delivered under the Act (including all documents filed with the
Commission during such period that are deemed to be incorporated by reference
therein), in each case as soon as available and in such quantities as you may
from time to time reasonably request and will also furnish copies of the
Prospectus to the NYSE in accordance with Rule 153 of the Rules and Regulations.
(f) The Company will make generally available to its security holders
as soon as practicable, but in any event not later than 15 months after the end
of the Company s current fiscal quarter, an earnings statement (which need not
be audited) covering a 12-month period that satisfies the provisions of Section
11(a) of the Act and Rule 158 of the Rules and Regulations.
(g) The Company, whether or not the transactions contemplated hereunder
are consummated or this Agreement is terminated, will pay all expenses incident
to the performance of its obligations hereunder (including, but not limited to,
any transaction fees imposed by any governmental or self-regulatory organization
with respect to transactions contemplated by this Agreement), will pay the
expenses of printing all documents relating to the offering, and will reimburse
the Agent from time to time upon request for its out-of-pocket costs and
expenses incurred in connection with the entering into of this Agreement and the
transactions contemplated by this Agreement, including, without limitation,
travel, reproduction, printing and similar
-10-
<PAGE> 11
expenses, as well as reasonable fees and disbursements of legal counsel retained
by the Agent.
(h) The Company acknowledges that the Structured Equity Shelf ("SES")
described herein is proprietary to the Agent and agrees not to engage any other
party (other than Nutter, McClennen & Fish ("NMF") or Coopers & Lybrand L.L.P.)
to provide advice in respect of or otherwise act as sales agent or underwriter
for any offering of securities involving SES or any similar method of offering
for a period of one year from the date hereof.
(i) The Company will apply the net proceeds from the sale of the Stock
as set forth in the Prospectus.
(j) The Company will not, directly or indirectly, offer or sell, any
shares of beneficial interest (other than the Stock and shares of beneficial
interest issuable pursuant to the Company's equity incentive plans or upon
conversion of outstanding convertible debt) or securities convertible into or
exchangeable for, or any rights to purchase or acquire, shares of beneficial
interest (other than such rights issued under the Company's equity incentive
plans during the period from the date of this Agreement through the final
Closing Date for the sale of Stock hereunder without giving the Agent at least
three business days prior written notice specifying the nature of the proposed
sale and the date of such proposed sale.
(k) The Company will, at any time during the term of this Agreement, as
supplemented from time to time, advise the Agent immediately after it shall have
received notice or obtain knowledge thereof, of any information or fact that
would alter or affect any opinion, certificate, letter and other document
provided to the Agent pursuant to Section 5 herein.
(l) Each time that (i) the Registration Statement or the Prospectus
shall be amended or supplemented (other than a supplement filed pursuant to Rule
424(b) under the Act that contains solely the information set forth in the final
paragraph of Section 3 of this Agreement or that does not relate to the Stock)
or (ii) there is filed with the Commission any document incorporated by
reference into the Prospectus (other than any proxy statement, Annual Report on
Form 10-K, Quarterly Report on Form 10-Q or a Current Report on Form 8-K, unless
the Agent shall otherwise specify), the Company shall furnish or cause to be
furnished to the Agent forthwith a certificate dated the date of filing with the
Commission of such amendment, supplement or other document, the date of
effectiveness of amendment, as the case may be, in form satisfactory to the
Agent to the effect that the statements contained in the certificate referred to
in Section 5(f) hereof which were last furnished to the Agent are true and
correct at the time of such amendment, supplement or
-11-
<PAGE> 12
filing, as the case may be, as though made at and as of such time (except that
such statements shall be deemed to relate to the Registration Statement and the
Prospectus as amended and supplemented to such time) or, in lieu of such
certificate, a certificate of the same tenor as the certificate referred to in
said Section 5(f), modified as necessary to relate to the Registration Statement
and the Prospectus as amended and supplemented to the time of delivery of such
certificate.
(m) Each time that (i) the Registration Statement or the Prospectus is
amended or supplemented (other than a supplement filed pursuant to Rule 424(b)
under the Act that contains solely the information set forth in the final
paragraph of Section 3 of this Agreement or that does not relate to the Stock)
or (ii) there is filed with the Commission any document incorporated by
reference into the Prospectus (other than any proxy statement, Annual Report on
Form 10-K, Quarterly Report on Form 10-Q or a Current Report on Form 8-K, unless
the Agent shall otherwise specify), the Company shall furnish or cause to be
furnished forthwith to the Agent and to counsel to the Agent a written opinion
of NMF, or other counsel satisfactory to the Agent, dated the date of filing
with the Commission of such amendment, supplement or other document and the date
of effectiveness of such amendment, as the case may be, in form and substance
satisfactory to the Agent, of the same tenor as the opinion referred to in
Section 5(d) hereof, but modified as necessary to relate to the Registration
Statement and the Prospectus as amended and supplemented to the time of delivery
of such opinion.
(n) Each time that the Registration Statement or the Prospectus shall
be amended or supplemented to include additional amended financial information
or there is filed with the Commission any document incorporated by reference
into the Prospectus which contains additional amended financial information
(other than by an amendment or supplement resulting from the filing by the
Company of a Current Report in Form 8-K, unless in the Agent's reasonable
judgment, such Current Report is of such a nature that a letter from the
Company's independent public accountant should be furnished) the Company shall
cause Coopers & Lybrand L.L.P. forthwith to furnish the Agent a letter, dated
the date of effectiveness of such amendment, or the date of filing of such
supplement or other document with the Commission, as the case may be, in form
satisfactory to the Agent, of the same tenor as the letter referred to in
Section 5(e) hereof but modified to relate to the Registration Statement and the
Prospectus, as amended and supplemented to the date of such letter.
SECTION 5. Conditions of Agent's Obligations. The obligations of the
Agent to sell the Stock as provided herein shall be subject to the accuracy, as
of the date hereof, and as of each Closing Date for any Pricing Period
contemplated under this Agreement, of the representations and warranties of the
-12-
<PAGE> 13
Company herein, to the performance by the Company of its obligations hereunder
and to the following additional conditions:
(a) No stop order suspending the effectiveness of the Registration
Statement shall have been issued and no proceeding for that purpose shall have
been instituted or, to the knowledge of the Company or the Agent, threatened by
the Commission, and any request of the Commission for additional information (to
be included in the Registration Statement or the Prospectus or otherwise) shall
have been complied with to the Agent's satisfaction.
(b) The Agent shall not have advised the Company that the Registration
Statement or Prospectus, or any amendment or supplement thereto, contains an
untrue statement of fact that in the Agent's opinion is material, or omits to
state a fact that in the Agent s opinion is material and is required to be
stated therein or is necessary to make the statements therein not misleading.
(c) Except as contemplated in the Prospectus, subsequent to the
respective dates as of which information is given in the Registration Statement
and the Prospectus, there shall not have been any material change, on a
consolidated basis, in the capital stock of the Company and its subsidiaries, or
any material adverse change, or any development involving a prospective adverse
change, in the condition (financial or other), business, prospects, net worth or
results of operations of the Company and its subsidiaries, or any change in the
rating assigned to any securities of the Company.
(d) The Agent shall have received at the date of the commencement of
the first Pricing Period hereunder (the "Commencement Date") and at every other
date specified in Section 4(m) hereof, opinions of NMF, counsel for the Company,
dated as of the Commencement Date and dated as of such other date, respectively,
in substantially the form attached hereto as Annex I.
(e) At or prior to the Commencement Date and at such other dates
specified in Section 4(n) hereof, the Agent shall have received a letter from
Coopers & Lybrand L.L.P., independent public accountants for the Company, dated
the date of delivery thereof, substantially in the form attached hereto as Annex
II and otherwise in form and substance satisfactory to Agent.
(f) The Agent shall have received from the Company a certificate, or
certificates, signed by the Chairman of the Board, the President or a Vice
President and by the principal financial or accounting officer of the Company,
dated as of the Commencement Date and dated as of each Closing Date contemplated
-13-
<PAGE> 14
by this Agreement, to the effect that, to the best of their knowledge based upon
reasonable investigation:
(i) The representations and warranties of the Company in this
Agreement are true and correct, as if made at and as of the
Commencement Date or the Closing Date for such Pricing Period (as the
case may be), and the Company has complied with all the agreements and
satisfied all the conditions on its part to be performed or satisfied
at or prior to the Commencement Date and each such Closing Date (as the
case may be);
(ii) No stop order suspending the effectiveness of the
Registration Statement has been issued, and no proceeding for that
purpose has been instituted or is threatened, by the Commission;
(iii) Since the date of this Agreement there has occurred no
event required to be set forth in an amendment or supplement to the
Registration Statement or Prospectus that has not been so set forth and
there has been no document required to be filed under the Exchange Act
and the rules and regulations of the Commission thereunder that upon
such filing would be deemed to be incorporated by reference in the
Prospectus that has not been so filed; and
(iv) Since the date of this Agreement, there has not been any
material adverse change, on a consolidated basis, in the business,
financial condition or results of operations of the Company and its
subsidiaries which has not been described in an amendment or supplement
to the Registration Statement or Prospectus (directly or by
incorporation).
All such opinions, certificates, letters and other documents will be in
compliance with the provisions hereof only if they are reasonably satisfactory
in form and substance to the Agent. The Company will furnish the Agent with such
conformed copies of such opinions, certificates, letters and other documents as
the Agent shall reasonably request.
SECTION 6. Indemnification and Contribution.
(a) The Company agrees to indemnify and hold harmless the Agent and
each person, if any, who controls the Agent within the meaning of Section 15 of
the Act or Section 20 of the Exchange Act, as follows:
(i) against any and all loss, liability, claim, damage and
expense whatsoever, as incurred, arising out of any untrue statement or
alleged untrue statement of a material fact contained in the
Registration Statement (or any
-14-
<PAGE> 15
amendment thereto), or the omission or alleged omission therefrom of a
material fact required to be stated therein or necessary to make the
statements therein not misleading or arising out of any untrue
statement or alleged untrue statement of a material fact contained in
any preliminary prospectus relating to the Stock to be sold hereunder
or the Prospectus (or any amendment or supplement thereto) or the
omission or alleged omission therefrom of a material fact necessary in
order to make the statements therein, in the light of the circumstances
under which they were made, not misleading;
(ii) against any and all loss, liability, claim, damage and
expense whatsoever, as incurred, to the extent of the aggregate amount
paid in settlement of any litigation, or any investigation or
proceeding by any governmental agency or body, commenced or threatened,
or of any claim whatsoever based upon any such untrue statement or
omission, or any such alleged untrue statement or omission, if such
settlement is effected with the written consent of the Company; and
(iii) against any and all expense whatsoever, as incurred
(including, subject to Section 6(c) hereof, the fees and disbursements
of counsel chosen by the Agent), reasonably incurred in investigating,
preparing or defending against any litigation, or any investigation or
proceeding by any governmental agency or body, commenced or threatened,
or any claim whatsoever based upon any such untrue statement or
omission, or any such alleged untrue statement or omission, to the
extent that any such expense is not paid under (i) or (ii) above;
provided, however, that this indemnity agreement shall not apply to any loss,
liability, claim, damage or expense to the extent arising out of any untrue
statement or omission or alleged untrue statement or omission made in reliance
upon and in conformity with written information furnished to the Company by the
Agent expressly for use in the Registration Statement (or any amendment thereto)
or any preliminary prospectus or the Prospectus (or any amendment or supplement
thereto).
(b) The Agent agrees to indemnify and hold harmless the Company and its
trustees and each officer of the Company, and each person, if any, who controls
the Company within the meaning of Section 15 of the Act or Section 20 of the
Exchange Act against any and all loss, liability, claim, damage and expense
described in the indemnity contained in subsection (a) of this Section, as
incurred, but only with respect to untrue statements or omissions, or alleged
untrue statements or omissions, made in the Registration Statement (or any
amendments thereto) or any preliminary prospectus or the Prospectus (or any
amendment or
-15-
<PAGE> 16
supplement thereto) in reliance upon and in conformity with written information
furnished to the Company by the Agent expressly for use in the Registration
Statement (or any amendment thereto) or such preliminary prospectus or the
Prospectus (or any amendment or supplement thereto).
(c) Any indemnified party that proposes to assert the right to be
indemnified under this Section 6 will, promptly after receipt of notice of
commencement of any action against such party in respect of which a claim is to
be made against an indemnifying party or parties under this Section 6, notify
each such indemnifying party of the commencement of such action, enclosing a
copy of all papers served, but the omission so to notify such indemnifying party
will not relieve it from (i) any liability that it might have to any indemnified
party otherwise than under this Section 6 and (ii) any liability that it may
have to any indemnified party under the foregoing provision of this Section 6
unless, and only to the extent that, such omission results in the forfeiture of
substantive rights or defenses by the indemnifying party. If any such action is
brought against any indemnified party and it notifies the indemnifying party of
its commencement, the indemnifying party will be entitled to participate in and,
to the extent that it elects by delivering written notice to the indemnified
party promptly after receiving notice of the commencement of the action from the
indemnified party, jointly with any other indemnifying party similarly notified,
to assume the defense of the action, with counsel satisfactory to the
indemnified party, and after notice from the indemnifying party to the
indemnified party of its election to assume the defense, the indemnifying party
will not be liable to the indemnified party for any legal or other expenses
except as provided below and except for the reasonable costs of investigation
subsequently incurred by the indemnified party in connection with the defense.
The indemnified party will have the right to employ its own counsel in any such
action, but the fees, expenses and other charges of such counsel will be at the
expense of such indemnified party unless (1) the employment of counsel by the
indemnified party has been authorized in writing by the indemnifying party, (2)
the indemnified party has reasonably concluded (based on advice of counsel) that
there may be legal defenses available to it or other indemnified parties that
are different from or in addition to those available to the indemnifying party,
(3) a conflict or potential conflict exists (based on advice of counsel to the
indemnified party) between the indemnified party and the indemnifying party (in
which case the indemnifying party will not have the right to direct the defense
of such action on behalf of the indemnified party) or (4) the indemnifying party
has not in fact employed counsel to assume the defense of such action within a
reasonable time after receiving notice of the commencement of the action, in
each of which cases the reasonable fees, disbursements and other charges of
counsel will be at the expense of the indemnifying party or parties. It
-16-
<PAGE> 17
is understood that the indemnifying party or parties shall not, in connection
with any proceeding or related proceedings in the same jurisdiction, be liable
for the reasonable fees, disbursements and other charges of more than one
separate firm admitted to practice in such jurisdiction at any one time for all
such indemnified party or parties. All such fees, disbursements and other
charges will be reimbursed by the indemnifying party promptly as they are
incurred. An indemnifying party will not be liable for any settlement of any
action or claim effected without its written consent (which consent will not be
unreasonably withheld).
(d) In order to provide for just and equitable contribution in
circumstances in which the indemnification provided for in the foregoing
paragraphs of this Section 6 is applicable in accordance with its terms but for
any reason is held to be unavailable from the Company or the Agent, the Company
and the Agent will contribute to the total losses, claims, liabilities,
expenses and damages (including any investigative, legal and other expenses
reasonably incurred in connection with, and any amount paid in settlement of,
any action, suit or proceeding or any claim asserted, but after deducting any
contribution received from persons other than the parties hereto, who also may
be liable for contribution) to which the Company and any one or more of the
Agent may be subject in such proportion as shall be appropriate to reflect the
relative benefits received by the Company on the one hand and the Agent on the
other. The relative benefits received by the Company on the one hand and the
Agent on the other hand shall be deemed to be in the same proportion as the
total net proceeds from the offering (before deducting expenses) received by
the Company bear to the total compensation (before deducting expenses) received
by the Agent from the sale of Stock on behalf of the Company. If, but only if,
the allocation provided by the foregoing sentence is not permitted by
applicable law, the allocation of contribution shall be made in such proportion
as is appropriate to reflect not only the relative benefits referred to in the
foregoing sentence but also the relative fault of the Company, on the one hand,
and the Agent, on the other, with respect to the statements or omission which
resulted in such loss, claim, liability, expense or damage, or action in
respect thereof, as well as any other relevant equitable considerations with
respect to such offering. Such relative fault shall be determined by reference
to whether the untrue or alleged untrue statement of a material fact or
omission or alleged omission to state a material fact relates to information
supplied by the Company or the Agent, the intent of the parties and their
relative knowledge, access to information and opportunity to correct or prevent
such statement or omission.
-17-
<PAGE> 18
The Company and the Agent agree that it would not be just and equitable if
contributions pursuant to this Section 6(d) were to be determined by pro rata
allocation or by any other method of allocation which does not take into account
the equitable considerations referred to herein. The amount paid or payable by
an indemnified party as a result of the loss, claim, liability, expense or
damage, or action in respect thereof, referred to above in this Section 6(d)
shall be deemed to include, for the purpose of this Section 6(d), any legal or
other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. Notwithstanding the
provision of this Section 6(d), the Agent shall not be required to contribute
any amount in excess of the amount by which the total actual sales price at
which Stock sold by the Agent exceeds the amount of any damages that the Agent
has otherwise been required to pay by reason of such untrue or alleged untrue
statement or omission or alleged omission and no person found guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Act)
will be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. For purposes of this Section 6(d), any person who
controls a party to this Agreement within the meaning of the Act will have the
same rights to contribution as that party, and each officer of the Company who
signed the Registration Statement will have the same rights to contribution as
the Company, subject in each case to the provisions hereof. Any party entitled
to contribution, promptly after receipt of notice of commencement of any action
against such party in respect of which a claim for contribution may be made
under this Section 6(d), will notify any such party or parties from whom
contribution may be sought, but the omission so to notify will not relieve that
party or parties from whom contribution may be sought from any other obligation
it or they may have under this Section 6(d). No party will be liable for
contribution with respect to any action or claim settled without its written
consent (which consent will not be unreasonably withheld).
SECTION 7. Representations and Agreements to Survive Delivery. All
representations, warranties and agreements of the Company herein or in
certificates delivered pursuant hereto, and the agreements of the Agent
contained in Section 6 hereof, shall remain operative and in full force and
effect regardless of any investigation made by or on behalf of the Agent or any
controlling persons, or the Company (or any of their officers, directors or
controlling persons), and shall survive delivery of and payment for the Stock.
-18-
<PAGE> 19
SECTION 8. Termination.
(a) The Agent shall have the right by giving notice as hereinafter
specified at any time at or prior to any Closing Date, to terminate this
Agreement if (i) any material adverse change, or any development involving a
prospective material adverse change, in the business, financial condition or
results of operations of the Company and its subsidiaries has occurred which, in
the reasonable judgment of such Agent, materially impairs the investment quality
of the Stock, (ii) the Company shall have failed, refused or been unable, at or
prior to the Closing Date, to perform any agreement on its part to be performed
hereunder, (iii) any other condition of the Agent s obligations hereunder is not
fulfilled, (iv) any suspension or limitation of trading in the Stock on the
NYSE, or any setting of minimum prices for trading of the Stock on such
exchange, shall have occurred, (v) any banking moratorium shall have been
declared by Federal or New York authorities or (vi) an outbreak or material
escalation of major hostilities in which the United States is involved, a
declaration of war by Congress, any other substantial national or international
calamity or any other event or occurrence of a similar character shall have
occurred since the execution of this Agreement that, in the reasonable judgment
of the Agent, makes it impractical or inadvisable to proceed with the completion
of the sale of and payment for the Stock to be sold by the Agent on behalf of
the Company. Any such termination shall be without liability of any party to any
other party except that the provisions of Section 4(g), Section 6 and Section 7
hereof shall at all times be effective. If the Agent elects to terminate this
Agreement as provided in this Section, the Agent shall provide the required
notice as specified herein.
(b) The Company shall have the right by giving notice as hereinafter
specified, to terminate this Agreement in its sole discretion on the date
occurring sixty (60) days after the date of this Agreement and every sixty (60)
days thereafter.
(c) Any termination of this Agreement shall be effective on the date
specified in such notice of termination; provided that such termination shall
not be effective until the close of business on the date of receipt of such
notice by the Agent or the Company, as the case may be. If such termination
shall occur during a Pricing Period, any Additional Shares and Average Market
Price Shares shall settle in accordance with the provisions of the second to
last paragraph of Section 3 hereof.
SECTION 9. Notices. All notices or communications hereunder shall be in
writing and if sent to the Agent shall be mailed, delivered, telexed or
telecopied and confirmed to the Agent at ___________________________________, or
if sent to the Company, shall be mailed, delivered, telexed or telecopied and
confirmed to the Company at 197 First Avenue, Needham Heights,
-19-
<PAGE> 20
Massachusetts 02194, Attention: David F. Benson, President. Each party to this
Agreement may change such address for notices by sending to the parties to this
Agreement written notice of a new address for such purpose.
SECTION 10. Parties. This Agreement shall inure to the benefit of and
be binding upon the Company and the Agent and their respective successors and
the controlling persons, officers and directors referred to in Section 6 hereof,
and no other person will have any right or obligation hereunder.
SECTION 11. Entire Agreement. This Agreement constitutes the entire
agreement and supersedes all other prior and contemporaneous agreements and
undertakings, both written and oral, among the parties hereto with regard to the
subject matter hereof.
SECTION 12. APPLICABLE LAW. THIS AGREEMENT SHALL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK WITHOUT
REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS.
SECTION 13. Limitation of Liability. The Declaration of Trust
Establishing the Company, dated August 6, 1985, as amended (the "Declaration"),
a copy of which is duly filed in the office of the Secretary of State of the
Commonwealth of Massachusetts, provides that the name "Meditrust" refers to the
Trustees under the Declaration collectively as Trustees, but not individually or
personally; and that no Trustee, officer, shareholder, employee or agent of the
Company shall be held to any personal liability, jointly or severally, for any
obligation of, or claim against, the Company. All persons dealing with the
Company, in any way, shall look only to the assets of the Company for the
payment of any sum or the performance of any obligation.
SECTION 14. Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
-20-
<PAGE> 21
If the foregoing correctly sets forth the understanding between the
Company and the Agent, please so indicate in the space provided below for that
purpose, whereupon this letter shall constitute a binding agreement between the
Company and the Agent. Alternatively, the execution of this Agreement by the
Company and its acceptance by or on behalf of the Agent may be evidenced by an
exchange of telegraphic or other written communications.
Very truly yours,
MEDITRUST
By:
Title:
ACCEPTED as of the date
first above written
[Name of Agent]
By:
Title:
21
<PAGE> 1
EXHIBIT 5
August 31, 1995
12742-392
Meditrust
197 First Avenue
Needham, MA 02194
Gentlemen:
Reference is made to the Registration Statement on Form S-3 (the
"Registration Statement"), which Meditrust, a Massachusetts business trust (the
"Company"), has filed with the Securities and Exchange Commission under the
Securities Act of 1933, as amended (the "Securities Act"), with respect to any
combination of the Company's shares of beneficial interest, without par value
(the "Shares"), debt securities (the "Debt Securities") which may be issued
under an Indenture (together with any supplement thereto, the "Indenture")
between the Company and a national bank as trustee (the "Trustee"), warrants to
purchase Shares and warrants to purchase Debt Securities (collectively, the
"Warrants"), valued in the aggregate at a maximum of $300,000,000, to be offered
on a continuous or delayed basis pursuant to the provisions of Rule 415 under
the Securities Act, and an indeterminate number of Shares as may be issued upon
any conversion of the Debt Securities and/or exercise of the warrants to
purchase Shares (the "Conversion Shares").
We have acted as counsel for the Company in connection with the
Registration Statement and are familiar with the proceedings taken and proposed
to be taken by the Company in connection with the authorization, registration,
sale and issuance of the Shares, the Debt Securities and the Warrants. We have
examined the Restated Declaration of Trust and By-laws of the Company and all
amendments thereto, and certificates of public officials and such other
documents, records and materials as we have deemed necessary in connection with
this opinion letter. Based upon the foregoing, and in reliance upon information
from time to time furnished to us by the Company's officers, trustees and
agents, we are of the opinion that:
1. Upon the due authorization, execution and delivery of the Debt
Securities by the Company in the manner referred to in the Registration
Statement and assuming any requisite authentication of the Debt Securities by
the Trustee and due qualification of the Indenture, if any, under the Trust
Indenture Act of 1939, as amended, and subject to the
<PAGE> 2
Meditrust
August 31, 1995
Page 2
terms of the Debt Securities being otherwise in compliance with then applicable
law, the Debt Securities will be duly issued and delivered by the Company and
will constitute the valid and legally binding obligations of the Company,
enforceable in accordance with their terms, except as such enforceability may be
subject to or limited by bankruptcy, insolvency, reorganization or other laws of
general application relating to or affecting creditors' rights or by general
equitable principles.
2. The Shares, when issued in compliance with the terms described in
the Registration Statement, and the Conversion Shares, when issued from time to
time upon conversion of the Debt Securities and/or exercise of the Warrants to
purchase Shares and in compliance with the terms described in the Indenture, if
any, concerning conversion of Debt Securities, will be duly and validly issued,
fully paid and non-assessable.
3. The Warrants, when issued in compliance with the terms described in
the Registration Statement, will be duly issued and legally binding obligations
of the Company, enforceable in accordance with their terms, except as such
enforceability may be subject to or limited by bankruptcy, insolvency,
reorganization or other laws of general application relating to or affecting
creditors' rights or by general equitable principles.
We understand that this opinion letter is to be used in connection with
the Registration Statement as finally amended, and hereby consent to the filing
of this opinion letter with and as a part of the Registration Statement as so
amended, and to the reference to our firm in the Prospectus under the heading
"Legal Matters." It is understood that this opinion letter is to be used in
connection with the offer and sale of the Shares, the Debt Securities and/or the
Warrants only while the Registration Statement is effective as so amended and as
it may be amended from time to time as contemplated by Section 10(a)(3) of the
Securities Act.
Very truly yours,
/s/ Nutter, McClennen & Fish
MJB/DGK/dmp
<PAGE> 1
EXHIBIT 8
August 31, 1995
12742-392
Meditrust
197 First Avenue
Needham, MA 02194
Gentlemen:
You have requested our opinion regarding the federal income taxation of
shareholders of Meditrust, a Massachusetts business trust (the "Company"), in
connection with the Registration Statement on Form S-3 with respect to the
Company's shelf registration of $300,000,000 in Company securities consisting of
a combination of shares of beneficial interest, debt securities and/or warrants
to be offered from time to time (the "Registration Statement"). The facts, as we
understand them, and upon which we rely in rendering the opinion expressed
herein, are set forth in the Registration Statement and in the Company's Current
Report on Form 8-K dated March 4, 1992 (the "Form 8-K"), which is incorporated
by reference in the Registration Statement.
Based on such facts, we are of the opinion that the statements
contained in the Form 8-K under the caption "Federal Income Tax Considerations,"
insofar as such statements constitute statements of federal income tax law, are
correct. No opinion is expressed as to any factual matter or as to any matter
not set forth therein. Our opinion is based on our interpretation of the
statutes, regulations, decisions and published administrative interpretations in
effect on the date hereof, and we can offer no assurance that such statutes,
regulations, decisions and published administrative interpretations will not be
amended, revoked or modified in a manner that would affect our opinion set forth
herein. Further, any variation in the facts from those set forth in the
Registration Statement or the Form 8-K may affect the conclusion stated herein.
We understand that this opinion letter is to be used in connection with
the Registration Statement, as finally amended, and hereby consent to the filing
of this opinion letter with and as a part of the Registration Statement as so
amended, and to the reference to our firm in the Prospectus under the heading
"Legal Matters." It is understood that this opinion letter is to be used in
connection with the offer and sale of the shares of beneficial interest, debt
<PAGE> 2
Meditrust
August 31, 1995
Page 2
securities and/or warrants only while the Registration Statement is effective as
so amended and as it may be amended from time to time as contemplated by Section
10(a)(3) of the Securities Act.
Very truly yours,
/s/ Nutter, McClennen & Fish
LJM/DGK/dmp
<PAGE> 1
EXHIBIT 12
Computation of Ratios of Earnings to Fixed Charges
(dollars in thousands)
<TABLE>
<CAPTION>
Six-Month
Period Ended
Year Ended December 31, June 30,
- -----------------------------------------------------------------------------------------------------------------
1990 1991 1992 1993 1994 1995
- -----------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Net Income $28,982 $34,225 $ 51,358 $ 63,636 $ 80,460 $55,112
Interest
Expense 43,494 56,886 58,159 62,193 67,479 33,724
------- ------- -------- -------- -------- -------
Total $72,476 $91,111 $109,517 $125,829 $147,939 $88,836
======= ======= ======== ======== ======== =======
Ratio 1.67 1.60 1.88 2.02 2.19 2.63
</TABLE>
For purposes of calculating the ratio of earnings to fixed charges for the years
ended December 31, 1990, 1991, 1992, 1993 and 1994 and the six-month period
ended June 30, 1995, net income has been added to interest expense and that sum
has been divided by such interest expense.
<PAGE> 1
Exhibit 23.2
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the incorporation by reference in the Registration Statement
of Meditrust on Form S-3 (dated August 31, 1995) of our reports dated January
16, 1995 on our audits of the consolidated financial statements and financial
statement schedules of Meditrust as of December 31, 1994 and 1993 and for each
of the three years in the period ended December 31, 1994, which reports are
included or incorporated by reference in the Meditrust Annual Report on Form
10-K for the year ended December 31, 1994. We also consent to the reference to
our firm under the caption "Experts."
/s/ Coopers & Lybrand L.L.P.
Boston, Massachusetts
August 31, 1995
<PAGE> 1
EXHIBIT 25
SECURITIES AND EXCHANGE COMMISSION
STATEMENT OF ELIGIBILITY
UNDER THE TRUST INDENTURE ACT OF 1939 OF A
CORPORATION DESIGNATED TO ACT AS TRUSTEE
Check if an Application to Determine Eligibility of a Trustee
Pursuant to Section 305 (b) (2) x
---
---------------------
FLEET NATIONAL BANK
(Exact name of trustee as specified in its charter)
U.S. NATIONAL BANK
(Jurisdiction of incorporation or organization
if not a U.S. national bank)
04-0317415
(I.R.S. employer identification no.)
111 Westminster Street, Providence, Rhode Island 02903
(Address of trustee's principal executive offices) (Zip code)
Not Applicable
(Name, address and telephone number of agent for service)
--------------------
Meditrust
(Exact name of obligor as specified in its charter)
<TABLE>
<S> <C>
Massachusetts 04-6532031
(State or other jurisdiction (I.R.S. employer
of incorporation or organization) identification no.)
197 First Avenue
Needham, Massachusetts 02194
(Address of principal executive offices) (Zip code)
</TABLE>
DEBT SECURITIES
(Title of the indenture securities)
<PAGE> 2
Item 1. General Information.
Furnish the following information as to the trustee:
(a) Name and address of each examining or supervising
authority to which it is subject.
Comptroller of the Currency, Washington, D.C.
Board of Governors of the Federal Reserve System,
Washington, D.C.
Federal Deposit Insurance Corporation, Washington,
D.C.
(b) Whether it is authorized to exercise corporate trust
powers.
Yes.
Item 2. Affiliations with Obligor.
If the obligor is an affiliate of the trustee, describe each such
affiliation.
None.
Items 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15 have been
omitted pursuant to General Instruction B.
<TABLE>
Item 16. List of Exhibits.
List below all exhibits filed as part of this statement of
eligibility and qualification.
<S> <C>
1.* A copy of the articles of association of the trustee as now in
effect. (See Exhibit T-1 (Item 12), Registration Statement No.
33-14628)
2.* A copy of the certificate of authority to the trustee to commence
business. (See Exhibit T-1 (Item 12), Registration Statement No.
33-43903)
3.* A copy of the authorization of the trustee to exercise corporate
trust powers. (See Exhibit T-1 (Item 12), Registration Statement
No. 33-43903)
4.* A copy of the bylaws of the trustee as now in effect. (See Exhibit
T-1 (Item 12), Registration Statement No. 33-14628)
</TABLE>
-2-
<PAGE> 3
<TABLE>
<S> <C>
5. Not applicable.
6. Consent of the trustee required by Section 321(b) of the Trust
Indenture Act of 1939.
7. A copy of the latest report of condition of the trustee published
pursuant to law or the requirements of its supervising or examining
authority.
<FN>
- -----------------------------
* The Exhibits thus designated are incorporated herein by reference.
Following the description of such Exhibits is a reference to the copy of the
Exhibit heretofore filed with the Securities and Exchange Commission, to
which there have been no amendments or changes.
</TABLE>
-3-
<PAGE> 4
NOTES
1. Inasmuch as this Form T-1 is filed prior to the ascertainment by the trustee
of all facts on which to base responsive answers to Item 2, the answers to said
Item is based on incomplete information.
2. Item 2 may, however, be considered as correct unless amended by an amendment
to this Form T-1.
-4-
<PAGE> 5
SIGNATURE
Pursuant to the requirements of the Trust Indenture Act of 1939, the trustee,
Fleet National Bank, a national banking association incorporated and existing
under the laws of the United States, has duly caused this statement of
eligibility to be signed on its behalf by the undersigned, thereunto duly
authorized all in the City of Providence, and State of Rhode Island on the 17th
day of August, 1995.
FLEET NATIONAL BANK
By: /s/ Christopher J. Lembo
--------------------------
Name: Christopher J. Lembo
Title: Trust Officer
-5-
<PAGE> 6
EXHIBIT 6
CONSENT OF TRUSTEE
Pursuant to the requirements of Section 321 (b) of the Trust Indenture Act
of 1939 in connection with the DEBT SECURITIES of MEDITRUST, Fleet National Bank
hereby consents that reports of examinations of Federal, state, territorial or
district authorities may be furnished by such authorities to the Securities and
Exchange Commission upon request therefor.
FLEET NATIONAL BANK
By: /s/ Christopher J. Lembo
--------------------------
Name: Christopher J. Lembo
Title: Trust Officer
Dated: August 17, 1995
-6-
<PAGE> 7
EXHIBIT 7
REPORT OF CONDITION
CONSOLIDATED REPORT OF CONDITION FOR INSURED COMMERCIAL
AND STATE-CHARTERED SAVINGS BANKS FOR JUNE 30, 1995
All schedules are to be reported in thousands of dollars. Unless otherwise
indicated, report the amount outstanding as of the last business day of the
quarter.
<TABLE>
<CAPTION>
SCHEDULE RC -- BALANCE SHEET C400
<S> <C> <C>
Dollar Amounts in Thousands RCFD Bil Mil Thou
- ------------------------------------------------------------------- --------------------------
//////////////////////////
ASSETS //////////////////////////
1. Cash and balances due from depository institutions (from //////////////////////////
Schedule RC-A): //////////////////////////
a. Noninterest-bearing balances and currency and coin (1)....... 0081 270,916 1.a.
b. Interest-bearing balances (2)................................ 0071 47,168 1.b.
2. Securities: //////////////////////////
a. Held-to-maturity securities (from Schedule RC-B, Column A)... 1754 19,929 2.a.
b. Available-for-sale securities (from Schedule RC-B, Column D). 1773 2,156,539 2.b.
3. Federal funds sold and securities purchased under agreements to //////////////////////////
resell in domestic offices of the bank and of its Edge and //////////////////////////
Agreement subsidiaries, and in IBFs: //////////////////////////
a. Federal funds sold........................................... 0276 30,171 3.a.
b. Securities purchased under agreements to resell.............. 0277 0 3.b.
4. Loans and Lease financing receivables: //////////////////////////
--------------------
a. Loans and Leases, net of unearned RCFD 2122 6,911,058 //////////////////////////
income (from Schedule RC-C).................................. //////////////////////////
b. LESS: Allowance for Loan and Lease RCFD 3123 220,547 //////////////////////////
Losses....................................................... //////////////////////////
c. LESS: Allocated transfer risk RCFD 3128 0 //////////////////////////
--------------------
reserve...................................................... //////////////////////////
d. Loans and Leases, net of unearned income, //////////////////////////
allowance, and reserve (item 4.a minus 4.b and 4.c).......... 2125 6,690,511 4.d.
5. Assets held in trading accounts................................. 2146 0 5.
6. Premises and fixed assets (including capitalized Leases)........ 2145 70,194 6.
7. Other real estate owned (from Schedule RC-M).................... 2150 16,697 7.
8. Investments in unconsolidated subsidiaries and associated //////////////////////////
companies (from Schedule RC-M).................................. 2130 2,394 8.
9. Customers' Liability to this bank on acceptances outstanding.... 2155 110 9.
10.Intangible assets (from Schedule RC-M).......................... 2143 152,077 10.
11.Other assets (from Schedule RC-F)............................... 2160 668,980 11.
12.Total assets (sum of items 1 through 11)........................ 2170 10,125,686 12.
--------------------------
<FN>
- -------------------
(1) Includes cash items in process of collection and unposed debit .
(2) Includes time certificates of deposit not held in trading accounts.
</TABLE>
-7-
<PAGE> 8
<TABLE>
<CAPTION>
SCHEDULE RC--CONTINUED
<S> <C> <C>
--------------------------
Dollar Amounts in Thousands //////////// Bil Mil Thou
- ----------------------------------------------------------------------------------------------
LIABILITIES //////////////////////////
13. Deposits: /////////////////////////
a.In domestic offices (sum of totals of columns A & C from Schedule
RC-E, part 1).... RCON 2200 4,797,298 13.a
(1) Noninterest-bearing(1) .......... RCON 6631 814,430 ////////////////////////// 13.a(1)
(2) Interest-bearing................ RCON 6636 3,982,868 ////////////////////////// 13.a(2)
--------------------------
b.In foreign offices, Edge and Apartment subsidiaries, and IBFs //////////////////////////
(from Schedule RC-E, part II).................................. . RCFN 2200 368,908 13.b
(1) Noninterest-bearing.............. RCFN 6631 102,970 ////////////////////////// 13.b(1)
(2) Interest-bearing................. RCFN 6636 265,938 ////////////////////////// 13.b(2)
14. Federal funds purchased and securities sold under agreements to //////////////////////////
repurchase in domestic offices of the bank and of its Edge and //////////////////////////
Agreement subsidiaries, and in IBFs: //////////////////////////
(a) Federal funds purchased.................................... RCFD 0278 1,208,457 14.a.
(b) Securities sold under agreement to repurchase.............. RCFD 0279 1,243,362 14.b.
15. (a) Demand notes issued to the U.S. Treasury................... RCON 2840 271,319 15.a.
(b) Trading Liabilities (from Schedule RC-D)................... RCFD 3548 0 15.b.
16. Other borrowed money: ////////////////////////// 16.
a. With original maturity of one year or less.................. RCFD 2332 1,012,438 16.a.
b. With original maturity of more than one year................ RCFD 2333 52,500 16.b.
17. Mortgage indebtedness & obligations under capitalized leases... RCFD 2910 0 17.
18. Bank's liability on acceptance executed and outstanding........ RCFD 2920 110 18.
19. Subordinated notes and debentures.............................. RCFD 3200 85,000 19.
20. Other liabilities (from Schedule RC-G)......................... RCFD 2930 321,509 20.
21. Total liabilities (sum of items 13 through 20)................. RCFD 2948 9,360,901 21.
//////////////////////////
22. Limited-Life preferred stock and related surplus............... RCFD 3282 0 22.
EQUITY CAPITAL //////////////////////////
23. Perpetual preferred stock and related surplus.................. RCFD 3838 0 23.
24. Common stock................................................... RCFD 3230 16,190 24.
25. Surplus (exclude all surplus related to preferred stock)....... RCFD 3839 224,528 25.
26. a. Undivided profits and capital reserves...................... RCFD 3632 528,181 26.a.
b. LESS: Net unrealized loss on marketable equity securities... RCFD 0297 (4,114) 26.b.
27. Cumulative foreign currency translation adjustments............ RCFD 3284 0 27.
28. Total equity capital (sum of items 23 through 27).............. RCFD 3210 764,785 28.
29. Total liabilities, limited-life preferred stock, and equity //////////////////////////
capital (sum of items 21, 22 and 28)........................... RCFD 3300 10,125,686 29.
--------------------------
</TABLE>
Memorandum
To be reported only with the March Report of Condition.
1. Indicate in the box at the right the number of the statement below that
best describes the most comprehensive level of auditing work performed
for the bank by independent external Number
auditors as of any date during 1992...RCFD 6724 2 M.1
<TABLE>
<S> <C>
1 = Independent audit of the bank conducted in 4 = Directors' examination of the bank peformed by
accordance with generally accepted auditing external auditors (may be required by state
standards by a certified public accounting chartering authority)
firm which submits a report on the bank
5 = Review of the bank's financial statements by
external auditors
2 = Independent audit of the bank's parent holding
company conducted in accordance with generally 6 = Compilation of the bank's financial statements
accepted auditing standards by a certified by external auditors
public accounting firm which submits a report 7 = Other audit procedures (excluding tax
on the consolidated holding company (but not on preparation work)
the bank separately)
8 = No external audit work
3 = Directors' examination of the bank conducted
in accordance with generally accepted auditing
standards by a certified public accounting firm
(may be required by state chartering authority)
<FN>
- ------------
(1) Includes total demand deposits and noninterest-bearing time and saving
deposits.
</TABLE>
-8-
<PAGE> 9
I, Giro S. DeRosa, Vice President & Controller of the above-named
bank, do hereby declare that this Report of Condition has been prepared in
conformance with the instructions issued by the appropriate Federal regulatory
authority and is true and correct to the best of my knowledge and belief.
/s/ Giro S. DeRosa
July 27, 1995
We, the undersigned directors, attest to the correctness of this
Report of Condition and declare that it has been examined by us and to the best
of our knowledge and belief has been prepared in conformance with the
instructions issued by the appropriate Federal regulatory authority and is true
and correct.
/s/ Thomas J. Skaler
/s/ B.S. Goldenberg
/s/ Robert J. Murray
-9-
